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Abstract

PROBING ALLOSTERIC, PARTIAL INHIBITION OF THROMBIN USING NOVEL
ANTICOAGULANTS
By Stephen S. Verespy III, B. S.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2016

Major Director: Umesh R. Desai
Doctor of Philosophy, Department of Medicinal Chemistry

Thrombin is the key protease that regulates hemostasis; the delicate balance
between procoagulation and anticoagulation of blood. In clotting disorders, like deep vein
thrombosis or pulmonary embolism, procoagulation is up-regulated, but propagation of
clotting can be inhibited with drugs targeting the proteases involved, like thrombin. Such
drugs however, have serious side effects (e.g., excessive bleeding) and some require
monitoring during the course of treatment. The reason for these side effects is the
mechanism by which the drugs’ act. The two major mechanisms are direct orthosteric and
indirect allosteric inhibition, which will completely abolish the protease’s activity. Herein

x
we sought an alternative mechanism called allosteric, partial inhibition, that has shown
promise to truly regulate coagulation. Partial inhibition through allosteric mechanisms are
well described for membrane-bound and oligomeric proteins. However proteases,
specifically monomeric proteases (i.e., thrombin), have not shown this phenomenon until
now. A small library of coumarin-based sulfated allosteric modulators (CSAMs) was
synthesized to target a surface region called exosite 2; mainly composed of highly
positively charged residues surrounded by hydrophobic patches. Studies revealed a noncompetitive mechanism of binding with a range of IC50s between 0.2-58 µM combined
with inhibitory efficacies (ΔY) between 22-73%; indicative of allosteric, partial inhibition.
The KD was determined for the most potent compound (3g; IC50 = 0.2 µM, ΔY = 47%) at
0.15 µM. 3g was observed to bind at exosite 2 through unfractionated heparin competition
and thrombin mutant studies. Additional computational studies were in agreement with the
mutant and competition studies, showing the sulfate of 3g binding within a pocket
containing R126 and R233. Fluorescence quenching and antithrombin inactivation rate
studies described a conformational change to thrombin’s active site in the presence of 3g,
supporting reduction of thrombin’s catalytic efficiency, without complete inhibition of
thrombin’s proteolytic activities. Coupled enzyme assays and gel electrophoresis showed
that in the presence of 3g, hydrolysis of fibrinogen (IC50 = 0.51 µM, ΔY = 94%) and
protein C activation (IC50 = 1.7 µM, ΔY = 91%) is fully inhibited. Alternatively, FXIII
activation was shown to be only partially inhibited by the presence of 3g, and FXI
activation did not show any significant activation or inhibition. 3g was also shown to be
active in human plasma and whole blood, but requiring much higher concentrations to

xi
induce an anticoagulant effect. Mice studies looking at the effects of 3g in vivo showed that
even at high concentrations, showed no abnormal bleeding or any other irregularities. This
work highlights a novel occurrence regarding thrombin’s allosteric functionality against
multiple endogenous substrates. This library of compounds may be useful in the future
development of allosteric inhibitors and probes that pose little to no risk of bleeding events
by inducing partial inhibition.

Key Words: Partial inhibition, thrombin, glycosaminoglycan mimetics, protease, exosite,
allosteric modulator, anticoagulants, catalytic efficiency, conformational allostery.
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CHAPTER 1 Introduction

1.1

Proteases
Biological systems rely heavily on enzymatic processes to function through a

number of catalytic pathways1. Of those, hydrolysis of peptide bonds through use of
proteases (also known as proteinases and peptidases) play major roles in homeostatic
regulation (e.g., immune response, blood coagulation, apoptosis, etc.) 1,2, as well as in
disease (e.g., cancer, viral/bacterial infection, cardiovascular disease, etc.) 3–6. The
translation of proteases must be well regulated due to their highly efficient nature of
catalysis. If up or down regulation of specific proteases is not maintained, several degrees
of dysfunction could result from degradation of non-ideal substrates or buildup of
substrates that could be potentially harmful. In the human genome alone 2-4% of the DNA
is made up of genes encoding for proteases; with an estimated number of 550 protease
genes known to date1. Proteases can be further categorized by traits relating to their
mechanism of action; and are done so in the following order of prevalence in humans. Of
the > 550 proteases, 34% make up the metalloproteases, 31% serine proteases, 26%
cysteine proteases, 5% threonine proteases, and 4% aspartic proteases1,2. These distinctions
are crucial in understanding the mechanism behind each individual class of proteases, so
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selective treatments may be developed to augment their effects if over produced in a
system.
1.1.1 Types and Mechanisms
Metalloproteases are named so because of their one or more cationic transition
metals located within their active (orthosteric) site. The most prevalent metal found in
metalloproteases (MPs) is zinc (Zn2+)7,8, but in some circumstances cobalt (Co2+) and
manganese (Mn2+) have also been found7,8. The transition metal within the active site is
typically held in place by coordination with two histidine residues and a glutamate residue
(three histidines may also be present)9,10. With regards to MP’s catalytic mechanism, there
are currently two theories on how the active site facilitates hydrolysis. The first is that
upon hydrolysis of a peptidyl bond, a water molecule coordinated with the Zn2+ is
activated by a secondary glutamate. In turn the Zn2+ also coordinates with the carbonyl
oxygen from the substrate and facilitates the hydrolysis of the substrate by the nucleophilic
water molecule9–11. The other theory suggests that the secondary glutamate acts as the
nucleophile instead of a water molecule, and forms an acyl intermediate with the substrate
carbonyl and the zinc. The theory suggests that a water molecule then behaves as a
nucleophile, but attacks the carboxylate of the secondary glutamate, causing deacylation
and hydrolysis product formation11.
The second most abundant class, serine proteases, catalyze numerous hydrolytic
reactions with high rates and efficiency for a multitude of endogenous macromolecules.
These proteases contain a serine residue in their active site and is coupled to a histidine
residue and an aspartate residue. This is generally known as a “catalytic triad” in which a
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nucleophile, an acid, and a base reside in close proximity to facilitate hydrolysis of a
peptide12,13. When a substrate enters the catalytic triad, the aspartate stabilizes the histidine
while it hydrogen bonds with the proton of the hydroxyl nucleophile of the serine14. The
hydroxyl then attacks the carbonyl forming a tetrahedral intermediate and the subsequent
electron movement hydrolyzes the amide bond producing an amine terminus and is
exported from the active site. As a water molecule enters the active site, the nitrogen of the
histidine again hydrogen bonds the one of the water’s protons, making the water
nucleophilic, where it attacks the in situ ester and forms an acyl intermediate. This then
causes a collapse of electrons back onto other half of the substrate forming the carboxy
terminus, regenerating the serine as the second product is released from the active site 12–14.
Serine proteases also contain a small pocket within their active site known as an oxyanion
hole, which uses backbone hydrogens from the amide bonds (from the serine and an
adjacent amino acid, usually glycine) to stabilize the negatively charged intermediates15.
Cysteine proteases, as their name suggests, utilize a thiol containing cysteine
residue at the center of their active sites. Although cysteine proteases are similar to the
serine proteases, the pKa of the thiol (normally ~8.3) is significantly lower; hovering near
3.3216,17. This has been shown to be due to the thiolate-imidazolium (or thiolateimidazolium-asparagine) ion pair that exists in the reactive site17. Thus depending on the
environment of the active site and the family of cysteine protease, a catalytic triad or a
catalytic dyad may exist18. With a cysteine protease’s catalytic triad, the same mechanism
as the serine protease can be observed, except the intermediary ester that is formed is now
a thioester, and the asparagine stabilizes the thiolate-imidazolium interaction between the
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Cys-His16–18. In the catalytic dyad, typically the same type of mechanism exists, in the
absence of the Asn, and instead is stabilized by electrostatic effects from ionizable groups
within 20 Å of the Cys-His; resulting in a nucleophilic attack from the thiolate on the
peptidyl substrate17. The mechanism proceeds with the thioester intermediate, releasing the
N-terminus product, addition of nucleophilic water to restore the cysteine thiol and release
the C-terminus product.
Threonine proteases are unique in that they utilize a secondary alcohol for their
nucleophile, rather than a primary nucleophile like the serine’s and cysteine’s. Due to the
secondary alcohol present, the γ-methyl group sterically blocks basic residues (i.e.,
histidine) responsible for deprotonating the alcohol. To remedy this, nature has constructed
threonine proteases to having the threonine be the N-terminal amino acid19. With this, the
γ’-hydroxyl faces the N-terminal amine, allowing the amine to behave as a base20. The
presence of a water molecule allows the amine to abstract a proton, and in turn the newly
formed hydroxyl deprotonates the γ-hydroxyl of threonine21. The threonine then attacks the
carbonyl of the substrate present in the active site, forming a tetrahedral intermediate,
which goes on to hydrolyzing the amide bond. The threonine is restored when the water
molecule stabilized by the N-terminal amine hydrolyzes the intermediary ester, releasing
the C-terminal product.
Lastly, the aspartic proteases utilize two aspartic acid residues existing with one as
the acid and the other as the conjugate base, aspartate. This class represents a small number
of the total protease presence in the human genome; only 15 of the 21 identified so far
have been discovered to be therapeutically relevant2. This however does not include non-
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mammalian proteases from viral, fungal, and parasitic sources (composed of >20
individual aspartic proteases)1. The mechanism is very simple in that the conjugate base
activates a water molecule, which in turn attacks the peptide bond of the substrate22–24. The
electrons transferred to the oxygen of the carbonyl in the tetrahedral intermediate, abstract
the proton of the second aspartic acid22–25. The hydrolysis of the substrate is then
completed by the second aspartate removing a proton of the tetrahedral intermediate
hydroxyl, causing the electrons to resonate back through the amide bond, forming a
carboxy terminus and an amine terminus. The resonance restores the aspartic dyad for
another substrate to be hydrolyzed.
1.1.2 Serine Protease Recognition Sequences
Comprehending the different protease mechanisms is an important aspect in
understanding how the individual proteases behave. However for this work, serine
proteases are the focal point. While their hydrolysis mechanism is straight forward, the
serine protease’s recognition of substrates is seemingly of more interest. Serine proteases
are unique in that they are highly plastic enzymes and able to adopt numerous structural
conformations to accommodate their substrate(s)13,26. This means that a protease can
hydrolyze multiple, structurally dissimilar proteins or peptide networks with similar kinetic
rates13,27–32. Although the specificity of substrate is very broad with the different families
of serine proteases, sequence selectivity is usually conserved within each family13,33,34. In
order words, the exact peptidyl cleavage sequence is crucial and varies between each
protease.
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For example, trypsin, is considered to be fairly promiscuous, and is most widely
known for its use in biochemical laboratories for digestion of other proteins. Trypsin’s
proteolytic mechanism involves hydrolyzing the C-terminus of a peptidyl linkage when the
position, P1 residue, is an arginine (R) or lysine (K). However, the residues proceeding and
preceding the P1 position directly affect the recognition and affinity. For most cases,
proline blocks cleavage if it is at the P1’ position, a caveat though is that if the positional
sequence, P4-P3-P2-P1-P1’-P2’, is XXWKPX or XXMRPX (where X is any amino acid),
the proline has no blocking capabilities35,36. Likewise, if the positional sequence is
XXC/DKDX, XXCKH/YX, XXCRKX, or XXRRH/RX, the hydrolysis is blocked35. The
understanding of this specificity and selectivity is critical when investigating active site
inhibitors of proteases for drug development. However, these competitive inhibitors simply
bind within the orthosteric pocket with a greater binding affinity (> KD), outcompeting
endogenous substrates. This route of inactivating a protease’s activity has been studied for
decades.
Another key example is the chymotrypsin-like protease, thrombin. It is broadly
used in vitro for biochemical assays and is the key protease in blood coagulation, which
will be discussed later, as the main topic of this work. Like trypsin, thrombin’s proteolytic
activity is at the C-terminal of arginine residues at P1 within a peptidyl sequence35,37.
Additional optimal conditions include when arginines are flanked by glycines at the P2 and
P1’ positions. Other favorable conditions are when the P4 and P3 positions are occupied by
hydrophobic residues, proline occupies P2, and for P1’ and P2’ to lack acidic residues35,37.
Further investigations into thrombin’s specificity of the P2-P4 positions when arginine is at
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P1 revealed several interesting observations. At P4, long chain, hydrophobic residues (e.g.,
isoleucine, leucine, norleucine, phenylalanine and to some extent tryptophan) were ideal
substitutions38. Most likely owing to thrombin’s S4 pocket being considerably
hydrophobic; containing isoleucine, methionine, leucine, and tryptophan. The P3 position
was shown to be non-discriminatory; with the exception of glutamate, which produced
little catalytic activity from thrombin39. Lastly at the P2 position, proline dominated
showing no other residues capable of producing comparable catalytic efficiency35,37–39.
This information is important in understanding thrombin’s natural substrate sequence
specificity, and how changes in thrombin’s substrates can have remarkably different
catalytic rates.
1.2

Venous and Arterial Thromboembolism
The relationship between protease activity and cardiovascular disease (CVD) is

strongly correlated. Both genetic and environmental factors have been shown to be key
activators of CVD40. Notably, there are two common types of CVD: venous
thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary
embolism (PE); and arterial thromboembolism (ATE), which includes ischemic stroke and
myocardial ischemia, leading to myocardial infarction40,41. Two simple distinctions
between the two diseases are the locations of a thrombus (blood clot) formed, which in
turn causes an embolism (occlusion) in either a vein or an artery, and the clinical
symptoms each disease articulates40. Although these diseases are classified as separate
entities, they share many common traits, risk factors, and have been shown be more related
than not40,42–44. The general mechanism of VTE is a result unabridged up-regulation of
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proteases within the coagulation system, while ATE has been understood to be directly
caused by activated platelets45,46. However as more investigations ensue, they suggest a
relationship between the two diseases40,42–44.
Distinctions and symptoms relating to venous thromboembolism as stated involves
thrombus formation within a vein resulting in occluded blood flow, swelling and pain.
DVT presents itself mostly in the “deep veins” including the femoral vein, pelvic vein, and
in some instances the cerebral veins43,47. PE blood clots are actually fragments of DVT
clots, which break off and travel to the lungs. This results in partial or full occlusion of the
pulmonary arteries which can be detrimental to the lung tissue containing the clot. It is
important to note that although PE blood clots occur in arteries, they are included in the
VTE description because they are caused directly by DVT clots.
Arterial thromboembolism generally considered to be more dangerous, due to their
location of formation. ATE’s typically form around areas that have experienced an arterial
rupture called an atheroma. This is usually caused by the buildup of plaques within the
arterial wall called atherosclerosis within the heart or brain45,46. Once the plaques induce an
atheroma, thrombosis ensues forming an occlusion that partially or fully blocks blood flow
to the specific area affected48. The result in the case of a blockage to heart is a myocardial
ischemia and to the brain is an ischemic stroke. The tissue suffers from loss of blood flow,
thus loss of oxygen, causing an infarction.
1.2.1 Prevalence
VTE and ATE have significant epidemiological impacts on world populations. It is
currently estimated that in the United States alone, venous thromboembolic events result in
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>250,000 incidence cases annually49. Concurrently, ~30% of patients have at least one
recurring episode within a 10-year period following initial diagnosis49. The mortality rate
varies year-to-year, but typically ranges from 60,000-100,000 deaths/year49. According to a
report by the American Heart Association, ischemic strokes brought on by ATE, result in >
675,000 incidence cases/year in the US alone, with about 170,000 of those being
reoccurrences49. Nearly 25% of those cases result in death each year. Looking at the world
population, > 39 million identified cases/year from ischemic stroke, owing to 11.13% of
deaths worldwide50. The same report goes on to stating that 735,000 Americans experience
myocardial infarctions each year, with 210,000 of those being repeated episodes 49,50. This
results in ~370,000 deaths/year in the US. For myocardial infarctions worldwide, > 7.2
million deaths occur each year; making it the leading cause of death49. These unsettling
statistics highlight the fact that although cardiovascular diseases have been relentlessly
studied, available treatments are not enough in providing long-term stasis of patients.
1.2.2 Serine Proteases of the Coagulation Cascade
The end goal for many scientists interested in preventing or combating CVDs is to
develop new, more effective treatments, or to identify new mechanisms that are able to be
targeted. However before understanding the various pharmacological treatments, one must
understand the concept behind one of the main driving forces for VTE and ATE, the
coagulation cascade. Under normal conditions, endothelial cells, which coat the interior of
blood vessels, produce prostacyclin (prostaglandin I2 or PGI2) and nitric oxide (NO) and
excrete them into blood flow. Combined, these two molecules act as vasodilators; while
PGI2 also acts to inhibit platelet activation51. Upon injury to the endothelium, collagen is
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exposed and tissue factor is released52. The glycoprotein von Willebrand factor (vWF),
binds to the collagen and mediates the binding of platelets to exposed collagen, which
induces initial activation of platelets53. The activated platelets undergo major structural
changes, becoming dendritic, and release granules containing a multitude of coagulation
factors, adhesion molecules, polyphosphates, adenosine diphosphate (ADP), calcium
(Ca2+), and thromboxane A2 (TXA2). ADP and TXA2 induce platelet recruitment,
activation, and aggregation; while the calcium is essential for several of the coagulation
factors to bind platelets53,54. The activated platelets expose phosphatidylserine on their
extracellular surface, as well as release polyphosphates, giving way to the two coagulation
pathways53,55.
The first coagulation pathway is called the intrinsic or “contact-activation”
pathway. The pathway is given that term because the protease cascade that ensues, is a
result of polyanionic interactions with the surface of the protease, factor XII55. Upon the
activation of platelets, small amounts of FXII come in contact with the phosphatidylserine
or the polyphosphates released by the platelets, inducing a conformational change,
activating FXII. The little FXIIa produced then activates kallikrein from prekallikrein. At
the same time, high molecular weight kininogen (HMWK) binds to the negatively charged
surface of the injured endothelium and the activated platelets, acting as a cofactor for more
kallikrein and FXIIa generation55,56. FXIIa in turn, activates factor XI in the presence of
calcium, initiating the intrinsic pathway55. As seen in Figure 1, FXIa goes on to activating
factor IX in the presence of calcium57. At this point, the cascade enters the common
pathway, where now FIXa and calcium activates factor X. Then FXa in complex with
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calcium, and phosphatidylserine activate small levels of thrombin from prothrombin, the
key protease of the coagulation cascade57–59.
To get to the same common pathway, the extrinsic pathway or “tissue factor”
pathway, is initiated by the actual trauma of the damaged blood vessel. Damage to the
endothelial cells exposes the subendothelium, which expresses high levels of
thromboplastin (tissue factor; TF). The TF forms a complex with plasma factor VII,
activating it, which subsequently activates both FIX and FX, completing the loop for the
common pathway59,60. As stated above, the extrinsic and intrinsic pathway generate low
levels of thrombin, which then goes on to performing multiple functions, including
amplifying its own production. Thrombin behaves as a procoagulant by activating factor
VIIIa, FIXa cofactor61; as well as activating factor V, a FXa cofactor61. As these cofactors
are activated and complexes with their respected enzymes are formed, the production of
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thrombin is greatly accelerated. When thrombin levels are sufficient, thrombin goes on to
hydrolyzing its main substrate, fibrinogen, into insoluble fibrin monomers. Thrombin
concurrently will activate factor XIII, a transglutaminase responsible for cross-linking the
fibrin monomers, forming the initial fibrin mesh that holds the activated platelets together
around the site of injury62. Thrombin can also recruit more activated platelets to the injury
site by binding with glycoprotein 1bα (GP1bα) and cleaving the protease-activated
receptors (PAR) 1 and 4 on the platelet surface63,64. Binding of thrombin to GP1bα (or
polyphosphates) also induces a feedback loop of thrombin activation by independently
activing more FXIa (see Figure 1)65,66.
1.2.3 Hypercoagulation: Current Treatments, Mechanisms, and Side Effects
As insinuated above, the concentration of zymogen and active proteases released by
platelets or that are free flowing in plasma play a critical role in contributing to blood
clotting, as well as disorders like hypercoagulation. Hypercoagulable states
(thrombophilia) are defined as when a patient has a higher tendency to form abnormal
blood clots due to several factors including genetics, medical conditions, or medication
being taken67. Predominantly, inherited factors are the most concerning, due to a patient
being unaware that they are predisposed. The most common type of thrombophilia is factor
V Leiden, a genetic mutation of the F5 gene, where factor V is translated68. The mutation
causes a sequence alteration at the codon for Arg506 at the activated protein C cleavage
site and substitutes with glutamine69. This mutation results in FVa:FXa complex remaining
active for 10-fold longer, producing considerably more thrombin. There is also support that
the lack of hydrolyzed FVa at R506, which is a cofactor for inactivation of FVIIIa, also
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allows FXa generation to be accelerated for longer periods of time69. Combined, these
would produce an abnormal acceleration of clot formation.
The second most common type of thrombophilia is the prothrombin gene mutation
(G20210A mutation) on the F2 gene. This single nucleotide mutation is part of the
noncoding region of the prothrombin gene, and thus does not cause any mutation to the
prothrombin itself. However, the mutation does cause an up-regulation of prothrombin
produced69,70. Statistical analysis of people with the G20210A mutation showed a 2-3-fold
increase in having a clotting event69,70, with those odds increasing if combined with other
risk factors, especially cancer.
In order to combat these thrombotic events, whether the source is congenital or
acquired, anticoagulant drugs have been used and continue to be in development for
treatment of DVT, PE, and arterial thrombosis. These drugs act in one of two ways, direct
or indirect. One of the first and most widely used anticoagulants is warfarin. Warfarin is a
coumarin-based small molecule that acts as an indirect anticoagulant. The mechanism by
which warfarin proceeds through targets the coagulation proteases requiring calcium, for
binding platelet surfaces71. Better known as a vitamin K antagonist, warfarin inhibits
vitamin K epoxide reductase, and effectively reduces the amount of vitamin K available as
a cofactor for γ-glutamylcarboxylase71–73. The γ-glutamylcarboxylase adds a γ-carboxylic
acid to glutamic acids on thrombin, FVII, FIX, FX, and protein C; called the Gla-domain,
responsible for binding calcium73. The warfarin in turn, causes production of coagulation
proteases that lack the Gla-domain, which renders them incapable to bind to platelets71.
This greatly reduces the ability for coagulation to ensue. Other indirect inhibitors of
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coagulation include glycosaminoglycans and their derivatives, which will be explained in
greater detail in Chapter 1 Section 3.
Although warfarin and its derivatives function very well to inhibit coagulation,
extensive monitoring of the drug per individual patient is required due to the complications
associated with warfarin therapy74. The main issue relating to warfarin is the high risk of
excessive bleeding events (hemorrhaging), even when taken as prescribed. Accidental
overdose greatly increases the risk for hemorrhages and induction of hemophilia-like
symptoms, with the only immediate reversal agent (antidote) being fresh frozen plasma 75.
Vitamin K can be introduced, but takes 4-6 hours before liver production of natural
coagulation factors containing the Gla-domain will be synthesized75.
Due to this potentially severe complication, researchers began investigating
alternative anticoagulants. These direct anticoagulants, bind directly to a protease’s active
site, rendering them incapable of catalyzing hydrolytic reactions76. To date, there are two
types of direct orthosteric anticoagulants available in the clinic, with more being
investigated for alternative targets. The two types include thrombin-specific and FXaspecific inhibitors. For thrombin-specific there are also two subtypes, univalent and
bivalent. The most notable univalent direct thrombin inhibitors (DTIs) are argatroban and
dabigatran. Argatroban is an injectable small molecule that has been approved for the
treatment of thrombosis and for patients experiencing heparin-induced thrombocytopenia
(HIT); a immunological condition brought on by the anticoagulant heparin, causing a
reduction in platelet concentrations77. The drug reversibly binds to thrombin’s orthosteric
site with an inhibitory constant (KI) of 40 nM and half-maximal inhibitory concentrations
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(IC50) of ~10 nM against platelet aggregation for free thrombin and ~20 nM for clot-bound
thrombin77,78. Dabigatran is an orally bioavailable small molecule that reversibly inhibits
thrombin’s orthosteric site with a KI of 4.5 nM79, as well as acts on thrombin in the clotbound state with an IC50 of 10 nM79. It is dosed as a prodrug, dabigatran etexilate, which
additionally contains an ethyl ester and hexyloxycarbonyl carbamide, to increase
hydrophobicity and membrane absorption80.
The bivalent DTIs indeed interact with the active site of thrombin, but also with a
secondary site called exosite 1. Exosite 1 is an allosteric site on thrombin adjacent to the
orthosteric site, and will be discussed in greater detail in Chapter 1 Section 4. The first
bivalent DTI to be discovered was hirudin. Hirudin, a 65 amino acid peptide found the in
the salivary glands of leeches, has an interesting mechanism of action81. It first recognizes
thrombin by binding to exosite 1 through mainly electrostatic and hydrophobic interactions
using its last 17 residues at the C-terminus81. Then the peptide chain, mainly through its
hydrophobic residues of the N-terminus binds within the active site pocket of thrombin,
occupying the S1-S4 pocket81. This discovery was a novel mechanism, both in the exosite
binding and the way it binds to thrombin’s active site pocket.
The direct FXa inhibitors (DXIs), like apixaban and rivaroxaban, act by targeting
FXa’s orthosteric site. The compounds are selective and do not inhibit thrombin or other
coagulation proteases, which subsequently do not have any direct effects on platelet
aggregation82. However, these two small molecules do inhibit both free and clot-bound
FXa, which indirectly inhibit thrombin activation. Both compounds have been approved
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for treatment of DVT and PE. Apixaban boasts a KI of 0.08 nM83 and rivaroxaban has a 0.4
nM KI84.
A large drawback of all of these anticoagulants is the risk of excessive and severe
bleeding. Although the DTIs and DXIs effectively treat thrombotic complications better
than warfarin, some side effects are more prevalent than compared to warfarin.
Argatroban, dabigatran, and rivaroxaban have been shown to have almost a 2-fold increase
in major gastrointestinal bleeding85. Argatroban also showed with >10% of patients in trial
experiencing minor bleeding in urinary organs, coupled with increased events of low
hemoglobin85. Hirudin clinical trials showed 2-10-fold increases in bleeding from injury
sites, drops in hemoglobin, and non-threatening bleeding (i.e., nose bleeds)85. Until
recently, none of these treatments had an approved, reliable emergency antidote. In 2015
however, idarucizumab was discovered to be a fast-acting antidote for dabigatran and its
anticoagulant effects86.
1.3

Glycosaminoglycans
An alternative treatment to the anticoagulants discussed above, along with the

oldest anticoagulant known, heparin and its many derivatives form a group of compounds
known as glycosaminoglycans (GAGs). GAGs as they exist in nature, are linear, complex,
carbohydrate structures composed of repeating, disaccharide units87. The type of
monomeric sugars that make up the disaccharides contain at least one amine in each
disaccharide. GAGs are biosynthesized in virtually all mammalian cells and are usually
attached to a protein or lipid, dubbed a proteoglycan or glycolipid87. Thus, GAGs are found
intracellularly, on the cell surface, and extracellularly, by means of excretion by some
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cells87. GAGs are one of the most unique biomolecules synthesized by cells because they
are non-template-based and can have variable modifications through epimerization,
sulfation, and acetylation.
GAGs can be broken down into five major classes: hyaluronan (HA), chondroitin
sulfate (CS), dermatan sulfate (DS), keratin sulfate (KS), and heparin/heparin sulfate
(H/HS). HA is the only non-sulfated GAG, composed of the disaccharide repeating units of
N-acetylglucosamine and glucuronic acid, which contains glycosidic linkages that
alternative between the anomeric carbons β1-4 and β1-3 (GlcNAcβ1-4GlcAβ1-3)87. CS is a
variably O-sulfated GAG made up of N-acetylgalactosamine and glucuronic acid. The CS
is linked through glycosidic bonds at the β anomeric carbons, 1-4 and 1-3 (GalNAcβ14GlcAβ1-3) with a sulfation pattern typically composed of the 4- and 6- position of the
GalNAc and the 2-position of GlcA87; although analysis has shown that some
disaccharides remain desulfated88. DS is very similar to CS and was once considered a
derivative of chondroitin sulfate, but the GlcA is isomerized, giving way to iduronic acid
(IdoA)87. Thus DS contains the GlcNAcβ1-4IdoAβ1-3 disaccharide linkage. KS is another
variably O-sulfated GAG consisting of galactose and N-acetylglucosamine (Galβ14GlcNAcβ1-3), but interestingly can be part of a branched glycan system through mannose
linking89. It can also be capped at the non-reducing end with fucoses or N-acetylneuraminic
acid89.
Lastly and more importantly for this work, heparin/heparan sulfate is a variably Osulfated and N-sulfonated GAG composed of α-glucosamine and β-glucuronic or αiduronic acid (GlcN[Ac/S]α1-4GlcAβ1-4/IdoAα1-4), depending on the individual
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disaccharide unit87. Variability of acetylation or sulfonation at the C-2 amine, as well as
isomerization within disaccharide units causing the anomeric carbon to change between α
and β, makes H/HS the most complex GAG sequence90. Heparin and heparin sulfate are
collective in grouping because their backbone disaccharides and sulfation/acetylation
patterns are generally the same, however heparin has been shown to be more sulfated than
HS; heparin contains ~2.7 sulfates per disaccharide versus HS having ≥ 1 sulfate per
disaccharide87. In humans, free heparin only consists of ~5% of the total H/HS, with HS
dominating in the proteoglycan form. Additionally, heparin is produced mainly in mast
cells, only being excreted under affliction87.
GAGs have a role in almost every biochemical mechanism in the body, with H/HS
most notably being involved within blood coagulation91. H/HS are indirect anticoagulants
that act as cofactors for endogenous serine protease inhibitors (serpins). These serpins,
such as antithrombin and heparin cofactor II, act to covalently inactivate the serine
protease by insertion of an inactivation loop into the active site of the protease. The serpin
initially interacts with the protease non-covalently, through a Michaelis-like complex,
similar to that of normal substrate interactions92. However, when the protease attempts to
hydrolyze the inactivation loop, the hydrolysis reaction is halted when the serine
covalently cleaves the C-terminal arginine within the inactivation loop92. Once the covalent
linkage occurs, the protease-bound serpin undergoes a conformational change, irreversibly
augmenting the active site pocket, disrupting the catalytic triad92. H/HS accelerates this
reaction by binding tightly to a distal site on the serpin (KD = low nM) and weakly binding
to a distal site on the protease (KD = low-to-mid µM)93. The protease therefore has a more
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dynamic interaction with the H/HS, allowing it to “walk” along the H/HS chain until it can
begin interacting with the serpin to form the initial Michaelis-like complex92,94. This
acceleration by H/HS increases the rate of the inactivation by 2000-4000-fold95,96.
In clinically relevant situations, exogenous heparin extracted from bovine or
porcine sources is used for anticoagulant treatment. The heparin derived in this fashion
must meet strict federal guidelines pertaining to the molecular weight, degree of sulfate,
and animal source97. Because full length heparin is not yet possible to chemically
synthesize, a number of enzymatic, chemoenzymatic, and synthetic steps have been taken
to create heparin derivatives like low-molecular weight heparin (LMWH; enoxaparin)98,
ultra-low-molecular weight heparin (ULMWH)99, and fondaparinux (pentasaccharide)100.
These heparins show lower
affinity towards plasma
proteins and as they
decrease in size, show less
effects accelerating serpinthrombin interactions, but focus mainly on facilitating antithrombin (AT)-FXa interactions;
with fondaparinux exclusively targeting AT-FXa (see Figure 2). The reasoning behind
making smaller heparin analogs is to combat heparin-induced thrombocytopenia (HIT),
mentioned earlier. In some patients, heparin triggers the formation of antibodies, that act
by activating platelets101. The activated platelets form microaggregates that lowers the free
platelet count in blood, but also can cause occlusions to blood capillaries101. Lower
molecular weight heparins reduce the amount of HIT observed as they get smaller.
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Unfortunately the drawbacks besides HIT as seen with other anticoagulants,
include major bleeding complications with heparin, LMWH, and fondaparinux. Although
LMWH and fondaparinux have reduced the risk for HIT, both showed higher prevalence of
major and minor bleeding after surgery, but overall equivalent or less bleeding for
treatment of DVT and PE compared to heparin102. This information suggests that although
there are downfalls for every type of anticoagulant, immense progress has been made
regarding safety of the drugs. However the notion of an “ideal” anticoagulant, which
would instill hemostasis to predisposed and afflicted patients, still looms.
1.4

Allostery and Conformational Change
Arguably one of the most important phenomenon that occurs with proteins and

within the study of enzymology, is the concept of allosterism. Allostery can be defined as
a distal interaction that induces a functional change to a protein (or enzyme), thereby
altering the primary site’s binding capability or catalytic efficiency103. Two major theories
have been at the forefront when describing allostery. The first was introduced by the
discovery of hemoglobin’s quaternary structure104. The theory suggested that structural
alterations of the protein’s conformation, induced by allosteric effectors, changed a
substrate’s binding affinity to the protein. This brought about the common explanation of
oxygen binding and the effect of 2,3-biphosphoglycerate (BPG) binding to hemoglobin
and how it effects the tense (T) and relaxed (R) states. It stated that hemoglobin in the
deoxy form (deoxyHb) has a low affinity for oxygen (T-state), but once an oxygen binds to
one of the four subunits, cooperativity takes over. This cooperativity induces
conformational change to the adjacent subunits, allowing those subunits to bind with
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oxygen, transitioning to oxyhemoglobin (oxyHb) or R-state105. When BPG binds to the
allosteric site of Hb, it stabilizes the T-state, in turn reducing the affinity for oxygen.
An alternative to this theory is the idea that an allosteric effector can broaden or
narrow the free energy within a protein’s conformational space106,107. This theory implies
that entropic events within the conformational space of the protein actually affects the
thermodynamics and the conformational dynamics, thus speeding up or slowing down the
motions of the protein itself106,107. Simply put, a distinct structural change does not need to
occur for a protein to respond to an allosteric effector108. Therefore when looking at
allosteric effects as a whole, one must take into consideration that if the no structural
change can be identified, then dynamic allostery must be taking precedence.
Allostery is a significant aspect of the coagulation cascade in that thrombin, the key
regulatory protease of the system, is highly regulated by allosteric interactions109,110.
Structurally, thrombin is a 37 kDa monomeric, serine protease with two distinct allosteric
sites called exosite 1 (residues include: K36, H71, R73, R75, Y76, R77, K109, and K110)
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and exosite 2 (residues include: R93, R97, R101, R126, R233, K235, K236, and K240); as
seen in Figure 3, using PDB ID: 3EQ0. This is in addition to the typical serine protease
catalytic triad composed of S195, H56, and D102. These exosites are highly cationic in
nature, owing to their ability to bind with anionic species like the sulfates of GAGs, the
tyrosine sulfates of many cofactors and peptides, and
D/E residues found in repeat sequences of many of
the same cofactors and peptides109. Additionally, the
exosites contain many hydrophobic pockets that aid
in ligand specificity and recognition109,111.
In conjunction with the active site and exosite
recognition, thrombin is known to have high degrees
of conformational plasticity112, allowing it to sample
a number of conformational states at any time; shown in Figure 4. Thrombin is thus
considered to have a large conformational space. Because of this flexibility, thrombin is
able to recognize and hydrolyze multiple substrates with only three recognition sites
(active site, exosite 1 and 2)112. Therefore, it is reasonable to assume that allosteric
effectors can induce either conformational or dynamic allostery. For example, when
heparin binds to exosite 2, no significant structural change is observed in crystallographic
studies113 or by using fluorescence techniques114. However, other endogenous ligands like
γ’-fibrinogen115 and GP1bα116 induce significant alterations to thrombin’s structure through
exosite 2-mediated interactions; sharing similar binding modes and residues to heparin. It
is also important to note that thrombin’s S1 pocket is significantly affected by the
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concentration of sodium in solution117. Na+ has been shown to bind with the backbone
carbonyl oxygens of thrombin’s Y184, R221 and K224, as well as with four water
molecules117. The binding of sodium coordinates the residues properly to give functional
geometry to the S1 pocket, allowing it to recognize the arginine residue of substrates117.
Thus, low sodium concentrations or blocking of this region would yield impaired
recognition of the substrate and reduced catalytic activity.
1.5

Glycosaminoglycan Mimetics
Having recognized that the exosites of thrombin can be selective for specific

sequences, to which the extent of these can be altered by the hydrophobicity of the ligand
(i.e., increasing the non-ionic binding energy), it was apparent that the design of synthetic
compounds could result in allostery-induced dysfunction of the catalytic site. Initial
development and studies used chemoenzymatically-derived sulfated, low molecular weight
lignins (LMWLs)118–120, which were purposed to mimic heparin binding. The difference
however was that backbone scaffold was significantly more hydrophobic by use of
phenoxypropanoic acid and dihydrobenzofuran repeat units instead of GlcN and
GluA/IdoA repeats118. Also the sulfation in the LMWLs was O-phenolic, replacing the
GAGs alkyl O-/N-sulfonation118.
Using chromogenic substrate hydrolysis assays, the LMWLs were shown to inhibit
thrombin’s activity by direct interaction of the heparin binding site (HBS), shown through
heparin competition and Michaelis-Menten kinetic studies with low nanomolar IC50s118,120.
These were confirmed as non-saccharide glycosaminoglycan mimetics (NSGMs) by means
of salt dependence studies and mutant studies. The LMWL’s binding affinities were
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reduced as the concentration of sodium was increased, suggesting that the multivalent
interaction of the sulfates was taking place, as seen with heparin119. The mutant studies
revealed that like heparin, R93 and R175 had significant impacts in binding with the
LMWLs showing a 7-8-fold reduction in inhibition when mutated121. Additional
electrostatic interactions included R101, K233, K235, and K240, which form the heparin
binding site121. However the notable difference is that although the LMWLs and heparin
bind at the same site, the LMWL induce allosteric inhibition of thrombin, while heparin
does not. Thus, the inhibition aspect must arise from the hydrophobic interactions of the
backbone scaffold.
Although the LMWLs displayed impressive inhibition concentrations, they were
not selective. Along with inhibiting thrombin, they also inhibited plasmin, FIXa, FXa,
FXIa, neutrophil elastase, and cathepsin G120. The LMWLs were also polydisperse,
variably sulfated, and had non-uniform linkages118. To combat some of these issues, a
synthetic polymer known as SbO4L was developed. Being SbO4L was fully synthetic and
the chemistry restrictive to one linkage being formed by a phenolic SN2 reaction, the
polymer formed was linked uniformly122. The polydispersity and average sulfation
presence were also uniform as compared to unfractionated heparin and LMWH used in the
clinics. Significant advances over the LMWLs was SbO4L’s log10-fold selectivity towards
thrombin and its ability to inhibit both thrombin and thrombin’s binding affinity to GP1bα
on platelets, effectively acting as an antithrombotic and antiplatelet agent122,123.
Stemming from the LMWL discoveries and concurrently with the SbO4L work was
the group of molecules known as sulfated allosteric modulators (SAMs), which more
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closely resembled small molecule-based inhibitors, rather than polymeric ligands. The
initial SAMs included sulfated monomeric, dimeric, trimeric, and tetrameric
benzofurans124–126. The synthesis of these molecules was to eliminate polydispersity, while
increase the non-ionic contributions to LMWL scaffold. As mentioned previously, the
LMWLs contained dihydrobenzofuran cores, which were easily attainable through the
cyclization of 1,2-dihydroxybenzene and acetoacetate124,125. This gave the benzofuran
heterocycle that was variously oligomerized in multiple reports and contained various
sulfation patterns, as well as a variety of protected and deprotected scaffolds124–126. The
general pattern of inhibition was that as the scaffolds elongated through oligomerization,
the inhibition became more potent. Additionally, the BFs showed much better inhibition
containing only one phenolic sulfate, and opening up the ester present in the structure to a
carboxylate, did not increase the potency124,125. Suggesting that the BFs act through mainly
hydrophobic interactions, while the sulfate is simply needed to “steer” the benzofuran to
the exosite127. Using the same techniques as for the LMWL, the BF family of compounds
showed that they bind to exosite 2 and specifically, the most potent BF dimer (IC50 = 5
µM) was shown to bind at R173128, while the benzofuran trimer (IC50 = 0.67 µM) was
shown to bind at the R233 residue of thrombin125. Modeling studies showed two distinctly
different binding sites for the dimer and trimer, and the tetramer did not have high
potency125. Overall this suggested that the inhibition of thrombin by the BFs was size
dependent and relied on hydrophobic interactions as well as the thrombin residues
donating hydrogen bonds to the H-bond acceptors of the BF molecules. It is important to
specify that the BF trimer was not selective for thrombin, and inhibited FXIa with nearly
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equipotent IC50s (0.8 µM for FXIa versus 0.67 µM for thrombin), by binding to FXIa’s
HBS129.
Other SAMs produced included quinazolinone, flavone, and tetrahydroisoquinoline
scaffolds. These compounds were structurally different from the BFs and so were their
specificity towards coagulation proteins. The quinazolinones/flavones (QAOs) were
synthesized as monomers or as dimers (homodimers or heterodimers with a flavone
moiety), which were linked by alkyl chains connected by 1,2,3-triazole(s), or by just alkyl
chains of varying lengths. The compounds were shown to be selective toward FXIa, over
thrombin, FXa, trypsin, and chymotrypsin127. The most potent QAO was a bisulfated
homodimer with a 1,2,3-triazole containing a 5 carbon alkyl linker, possessing an IC50 of
59 µM127. Alteration of the linkage from the 1- and 4-position to the 1,2,3-triazole to 1and 5-position led to ~2-fold drop in potency, suggesting that the triazole geometry plays a
significant role in binding to FXIa127. Alternatively, the tetrahydroisoquinolines (THIQs)
were found to be antithrombin accelerators for FXa inactivation. The THIQs accelerated
the inactivation of FXa by ~79-fold, but doing so with low potency130. However, an
interesting point to take away is that the relatively similar scaffolds have remarkably
different specificities and induce very different effects. Some act as direct, allosteric
inhibitors, that bind to the HBSs of proteases, while others bind to the HBSs and act as
heparin does in acceleration of AT inactivation.
1.6

Partial Inhibition
One aspect of allosteric inhibition that has been hinted at by previous data, was the

observation that some compounds, specifically SbO4L and BF trimer, exhibit submaximal
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inhibition of thrombin. In lay terms,
even at saturation of the ligand, the
protease remains active and able to
hydrolyze substrate. In graphical terms
(dose-response profiles), partial
inhibition is identified by the ΔY
(efficacy of inhibition) where the ΔY >
20% and < 80% (Figure 5). What is of
interest is the principle that while the ligand is inhibiting the protease, it remains partially
active towards the small substrate. This phenomenon could translate into multiple
downstream effects. For instance, if there is an alteration to thrombin’s pocket, endogenous
substrate may not be as recognizable or there may be activation when there is typically
inhibition131. Another possibility is that the catalytic efficiency is reduced, thereby slowing
the enzyme’s hydrolysis rate due to dysfunction of the S1 pocket or catalytic triad 132.
Furthermore, partial inhibition is a rare event in enzymes, especially with thrombin being a
monomeric protein. The typical proteins or enzymes that experience partial inhibition are
multimeric proteins such as receptors/membrane-bound proteins or multimeric proteins.
There are a multitude of examples for allosteric inhibitors inducing partial
inhibition of receptor/membrane-bound proteins. Likewise, the examples include not only
the typical structural conformational changes, but also conformational dynamic changes.
Recently, two examples of partial agonism explained by conformational dynamics have
been reported describing ionotropic and metabotropic glutamate receptors, respectively.
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The first report used crystallography and computational simulations which compared
agonist, partial agonist and antagonist ligand volumes bound to the binding site with
calculated free energy surfaces. The study showed that increasing the ligand size, lowered
the agonist efficacy; meaning that the free energy’s minima narrowed, reduced, or a
combination of the two133. This was indicative of small ligands being agonists, and as their
size increased, they became partial agonists or antagonists. Thus, the free energy diagrams
for each ligand may be used to predict if a ligand would act as a partial agonist or not.
Furthermore, the curvature of the free energy graphs may be correlated with the energies
relating to the glutamate channel’s opening or closing in response to a ligand, but with a
caveat that the simulations were performed using a monomer of the receptor and not the
full tetrameric structure133.
The second report takes this notion a step further where they investigated the
glutamate receptors using a partial agonist and monitoring the FRET changes at the dimer
interface of the ligand binding domain. They successfully demonstrated that the partial
agonist, DCG-IV, did not induce full occupancy of the low FRET state, even at saturating
levels; unlike the full agonist, which occupied the high FRET or active state 134.
Additionally, saturating concentrations of DCG-IV was able to keep dynamics near the
basal state of the receptor. This was also compared to full agonist, which showed that its
induced dynamics were dramatically slower, in looking at FRET traces134. The last major
aspect described that mutations made at conserved sequences of transmembrane (TM)
domains, positive allosteric modulators (PAMs) that bind at those TM domains drastically
increase the efficacy and affinity of the DCG-IV134. This supported the notion that the TM
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domains are directly linked to the ligand binding domain, an important feature the first
report hypothesized.
A caveat regarding this partial agonism is that these reports indeed showed partial
inhibition through conformational dynamics, but did not use allostery. This is an important
aspect to take into consideration because again, receptors are multimeric proteins, but not
enzymes. Therefore, their mechanisms of action are vastly different and are difficult to
make comparisons to. Although many allosteric agonists exist, they do not all directly
cause partial inhibition in receptors135. They can however enhance or modulate the partial
agonist, as seen in the example of DCG-IV and the PAM of the TM domains134. An
example however of an allosteric partial antagonist examines the structure activity
relationship of the 5-(phenylethynyl)pyrimidine scaffold. They showed that by varying
small structural changes to the scaffold, it changed the allosteric activity from partial
antagonist (71% response) to full antagonist (99% response)136. They concluded from this
study that the allosteric partial antagonism is not conserved to the general scaffold because
of the large variations in the activity of the inhibitor on the receptor136. This demonstrates
the high sensitivity of an allosteric site and that minor changes can have dramatic effects
on the outcome, most likely due to dynamics. To look at more classical examples of
allosteric partial inhibition, one must turn to a recently discovered inhibitor of a
phosphodiesterase, which is most relevant to this work.
The study on phosphodiesterase 4 (PDE4) examines the notion of an allosteric
partial inhibitor in order to aid in the prevention of side effects from patient using
orthosteric inhibitors of PDE4, which can cause abnormal cAMP concentrations in cells 137.
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Their evidence suggests that the PDE4 acts a dimer with negative cooperativity and can be
within multiple conformations; so as in saying only one of the two binding sites may be
open or closed at any time. Their lead designed compound was shown to be 1000-fold
more selective for the PDE4 isoform137. The study had observed that their lead compound
acted by shifting the binding of two key hydrophobic residues at the active site and
predicted interactions with the residues involved in binding the Zn2+ metal137; which is
linked to conformational allostery. The overall partial inhibition was > 50% with an IC50 of
2 nM, while also decreasing the kcat/KM of one of the active sites137. Additionally, the
cAMP levels in the cell cultures were not shown to be elevated, insinuating that the
allosteric partial inhibitor was indeed perform its enzymatic duties137.
The work described herein provides several details of partial inhibition by allosteric
and non-allosteric structural conformational changes and conformational dynamics.
Convincingly, there is a plethora of information regarding partial inhibition, but only with
regard to higher multimeric proteins, with the last study involving a dimer. One important
factor that separates oligomeric proteins with enzymes is that the for enzymes, only
allosteric effectors can induce partial inhibition135. With the receptors, the partial inhibition
can be induced by an allosteric modulator or by a ligand within the main ligand binding
domain, because the receptors act through channel opening and closing. If a ligand binds to
the enzyme active site, there is an all-or-none phenomenon where partial inhibition
fundamentally cannot occur. However, allostery offers up that accessibility if the ligand
induces a specific change to the structure or to the dynamics of the enzyme. The following
work describes the first known compound to induce allosteric partial inhibition of a
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monomeric enzyme, thrombin, its mechanism of inhibition, as well as a number of
interesting actions on endogenous substrates.
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CHAPTER 2 Coumarin-Based Sulfated Allosteric Modulators

Over the past decade, our lab has presented multiple works on the development of
non-saccharide glycosaminoglycan mimetics (NSGMs). These NSGMs began as
chemoenzymatically and fully synthetically produced , lignin-based polymers presenting
diverse arrangements of O-sulfates and carboxylates114. The first generation of NSGMs
were plagued with difficult characterization and separation; resulting in heterogeneous
mixtures and diverse conformational sequences122. Stemming from these polymers came
small molecules composed of heterocyclic cores, some mimicking the lignins, decorated
with O-sulfates synthesized from phenolic moieties. These heterocyclic cores included
benzofurans, quinazolinones, and flavones that were analyzed from monomeric cores to
tetrameric cores, in some instances. The addition of heterocyclic cores to produce
monomers through tetramers was done in two manners, direct conjugation or with varying
linkers. To this, the development of more than 150 diverse sulfated allosteric modulators
(SAMs) has led to a number significant advances within the fields of regulating
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coagulation124,125,127,129,130,138 and inhibition of cancer stem cell proliferation and
differentiation139.
We chose to expand the diversity and functionality of the SAM libraries, which led
us to study coumarins as the heterocyclic scaffold of choice for several reasons. A number
of coumarins are commercially available with diverse, synthetically accessible handles,
which greatly reduces the number of steps involved with synthesis. Coumarins are
pharmacologically relevant; the best and most relevant example of this is the vitamin K
antagonist, warfarin, which utilizes a coumarin backbone71. The coumarin scaffold offers a
structurally diverse core compared to the other heterocycles in the library, like the flavones
and quinazolinones.
We chose to focus on the coagulation cascade to examine whether these coumarinbased sulfated allosteric modulators (CSAMs) were efficacious against any of the
pharmacologically relevant proteases involved. Our earlier work on designing/discovering
allosteric modulators of thrombin showed that the sulfated scaffolds exhibited allosteric,
full inhibition (ΔY = 80–100%) at saturation124–127. However, an interesting observation
made with the lignin SbO4L and one of the benzofuran trimers was that at saturating
concentrations of the inhibitors, thrombin remained partially active (ΔY = 20-79%)122,124.
This idea of allosteric, partial inhibition was intriguing and sought after with the CSAMs.
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2.1.

Synthesis of First and Second Generation CSAMs
Sulfated coumarins were synthesized using either a protection–deprotection

strategy or a selective reaction strategy, which enabled the generation of the desired
number of free O-phenolic groups that could then be sulfated in a final step using sulfur
trioxide–trimethylamine complex140,141. Initially, O-methylated analogs are deprotected
using boron tribromide (BBr3) producing the free hydroxycoumarin scaffolds. The
hydroxycoumarins were then sulfated using microwave assisted sulfation (MWAS),
requiring sulfur trioxide trimethylamine complex (SO3.N(CH3)3), triethylamine (TEA) as a
base, and acetonitrile (ACN) as the solvent. First and second generation dimeric species
were also considered due to previous studies indicating that spanning a greater radius with
larger compounds increased potency. The second generation dimers were chosen to
represent the most promising compounds, with increased sulfation. For the first generation
dimeric species, the hydroxycoumarins were alkylated selectively with either propargyl
bromide, 1-bromo-3-chloropropane, or 1-bromo-4-chlorobutane. Subsequently, the
chloropropane or chlorobutane was reacted with sodium azide, to produce the alkylazide.
To form the dimeric compounds, the coumarin alkylazide and propyne groups were reacted
through copper (I)-assisted azide-alkyne cycloaddition (CuAAC). The dimeric precursors
were then sulfated using MWAS, resulting in a O-sulfate trimethylamine complex. The
second generation CSAMs first had their catechol moieties selectively protected using the
diphenylmethane (DPM) group, proceeded through the first alkylation steps, and was
deprotected. This deprotection prior to azidation and CuAAC was selected due to the lack
of dimeric product formation when the DPM was present. The free hydroxyls were then

35
sulfated using the MWAS. For all sulfated compounds, an additional step using cation
exchange chromatography ensured the alkylammonium sulfates were exchanged to sodium
sulfates and lyophilized to produce the final compound.
Collectively, the overall synthesis resulted in a 36 compound library of first
generation CSAMs (Figure 9). Then followed by two second generation compounds,
which contained higher degrees of sulfation of the two most promising molecules. Thus in
total, a 38 compound library was successfully synthesized exploiting various sulfation
patterns, substituent placement, and monomeric/dimeric species.
2.1.1 Experimental Details
For O-methylated coumarins, 50-100 mg of the starting material were suspended in
5 mL of dry DCM and subjected to 1.5 eq. per oxygen atom of 1.0 M BBr3 solution at -78
˚C under N2 atmosphere. The solutions were stirred for 5 h, allowed to reach room
temperature (rt), following which the solutions were again cooled to 0 ˚C and 6 mL od
water (or 1:1 water/methanol) were slowly added with stirring to quench the reaction over
the course of 10 minutes. The biphasic solution was then condensed in vacuo and was
taken up in 20 mL of ethyl acetate to which 15 mL of saturated ammonium chloride
solution was sequentially added. The mixture was transferred to a separatory funnel where
the organic phase was extracted and the aqueous phase was followed by two washes of 1020 mL of ethyl acetate. The organic layers were pooled, washed with brine, dried over
anhydrous Na2SO4, and then condensed in vacuo. The residues were taken up in minimal
DCM (~2 mL), dry-loaded onto silica gel and purified via normal phase flash
chromatography (0-70% ethyl acetate/hexanes). Fractions that contained the O-
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demethylated products were pooled and condensed in vacuo to yield white or yellow solids
in 87 – 98%; yielding precursors for products of 2w-2y (Figure 6).
To prepare dimeric CSAMs 3a-3f (Figure 7), we began with 150 mg of O-methoxy
coumarins, which were suspended in 5 mL of DCM in a round-bottom flask, brought down
to -78 °C and 1.5 equivalence per oxygen atom of 1.0M BBr3 in DCM was added dropwise
to the stirred solutions. The reactions proceeded for 5h as the temperature rose from -78 °C
to room temperature. To quench the reactions, the round-bottom flasks were placed in ice
baths to bring the reaction temperature to 0 °C. To the flask, 10 mL of 1:1 water:methanol
was added to reactions, effectively demethylating the coumarins. The volatile components
were condensed in vacuo and were taken up in 20 mL of ethyl acetate and 20 mL of
saturated ammonium chloride solution. The solution was transferred to a separatory funnel,
the organic layer was extracted and the aqueous phase was washed twice with 10 mL of
ethyl acetate. The organic layers were pooled, washed with brine, and dried over
anhydrous Na2SO4 and then concentrated in vacuo. The residues were taken up in minimal
DCM (2-3 mL), dry-loaded onto silica and purified by normal phase flash chromatography
(0-70% ethyl acetate:hexanes). The fractions containing the deprotected analogs were
pooled and concentrated in vacuo, yielding 75-96%.
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This yielded analogs containing two phenolic hydroxyl groups at the 7-position and
the 3-(4’-phenyl)-position. These two phenols were predicted to have different pKa’s and
thus by controlling the equivalence of base and electrophilic alkyl group, could selectively
alkylate one hydroxyl over the other. These analogs were taken up in 5-10 mL of dry DMF
and treated with 0.5-1.0 molar equivalence of Cs2CO3. The solution was stirred for 10
minutes and 0.9-1.0 molar equivalence of 1-bromo-3-chloropropane or 1-bromo-4chlorobutane was added slowly to the solution over a period of 20 minutes. The reaction
was allowed to continue stirring overnight (24 hours) at room temperature. Upon complete
consumption of the starting material (monitored by TLC), the reaction was quenched with
5 mL of 1.0 M HCl, 5 mL of water, and extracted with 20 mL of ethyl acetate. The
aqueous phase was washed twice with 10 mL of ethyl acetate and discarded. The organic
layers were pooled, washed with 20 mL brine, dried over anhydrous Na2SO4, and
concentrated in vacuo. The residue was taken up in DCM, dry-loaded onto silica, and
purified by normal phase flash chromatography. The separation yielded three major peaks
that corresponded to three products; the first peak as the dialkyated species, the second and
most prominent peak as the 7-alkylated species, and the third peak was the 3-(4’hydroxyphenyl) alkylation. The major peak, which contained 66-83% yield of products
was chosen to move forward as the one half of the dimer and characterized by 1H-NMR to
confirm structure and position of the alkyl group.
Subsequently, the alkylchloride moiety was subjected to an azide substitution
reaction to afford the alkylazide handle. To proceed with this, 1.5 equivalence of sodium
azide was added in one portion to a stirred solution of the coumarin-alkylchloride in 5 mL
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of DMF within a 10 mL microwave tube. The tube was then moved a CEM Discover
microwave reactor and reacted for 5 hours at 70 °C. Upon completion, the contents were
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diluted with 3 washes of 10 mL ethyl acetate and separated with 30 mL of water. The
organic layer was washed multiple times with 10 mL of water to remove excess DMF. The
organic layer was then washed with brine, dried over anhydrous Na 2SO4, and concentrated
in vacuo. The residue was saved without further purification. The confirm the identity of
the compound, 1H-NMR showed a distinct up-field shift of the adjacent CH2 and FT-IR
was used to confirm the presence of the azide moiety ~2100 cm-1.
Once the alkylazide was prepared, the alkyne handle needed for the cycloaddition
was synthesized. The starting dihydroxy coumarin was transferred into a round bottom
flask where 5 mL of dry DMF was added and stirred. To this, 0.5-1.0 molar equivalence of
Cs2CO3 was added and stirred for 10 minutes. Following, 0.9-1.0 molar equivalence of
80% propargyl bromide solution was slowly added to the stirred solution over the course
of 10 minutes. The reaction was allowed to proceed overnight and monitored by TLC until
all the starting material was consumed. The reaction was then quenched with 10 mL of
1.0M HCl and diluted with water. 20 mL of ethyl acetate was added and the mixture was
transferred to a separatory funnel. The organic layer was separated and the aqueous layer
was washed twice with 10 mL of ethyl acetate to remove residual compound. The organic
layers were pooled, washed with brine, dried over Na2SO4, and concentrated in vacuo. The
residue was taken up in minimal DCM (2-3 mL) and dry-loaded onto silica gel for normal
phase flash chromatography. The products, similarly to the alkylchloride, displayed three
major peaks. The major second peak was identified by 1H-NMR to confirm positional
conformation of the propyne moiety in 58-89% yields.
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Once both the azide and alkyne handle were produced, the coupling reaction could
ensue. The coupling employed typical copper(I)-assisted azide alkyne cycloaddition
(CuAAC) conditions where the azide and alkyne substituents were each dissolved in 1 mL
of DMF mixed into a solution of 5 mL of 4:1 DMSO:DMF. After stirring for 10 minutes, 7
mol% of sodium ascorbate solubilized in water was added to the solution and stirred for an
additional 10 minutes. To this, a solution of 3 mol% of 10 mM 1:1 CuSO4∙5H2O:tris-[(1benzyl-1H-1,2,3-triazol-4-yl)methyl]amine in 55% DMSO was added to the stirred
solution and allowed to react overnight at room temperature. After the allotted time, the
stirred solution was quenched by adding a few drops of 10% NH4OH (aq) and then flushed
with 20 mL of water. A yellow to white precipitate formed and was filtered off. The
precipitate was then taken up in 20 mL of ethyl acetate and washed with 5 mL of 1.0M
HCl and 15 mL of water. The aqueous phase was discarded and the organic phase was
washed with brine and dried over anhydrous Na2SO4. The organic phase was concentrated
in vacuo and dry-loaded onto silica for normal phase flash chromatography. The desired
product was isolated using 0-100 % ethyl acetate:hexanes, then 0-10 % methanol:DCM
giving 72-94% yields and confirmed by 1H-NMR.
The last synthetic step involved microwave-assisted sulfation. The free
hydroxycoumarins (demethylated monomers (2w-2y), free hydroxycoumarins (1a-1d; 2a2v) commercially obtained and synthetic dimers (3a-3g)) were taken up in 5 mL of
acetonitrile (ACN), placed into a 10 mL microwave tube, and to it 6 molar equivalence of
sulfur trioxide trimethylamine complex (SO3∙N(CH3)3) per OH was added and stirred.
Subsequently, 10 molar equivalence of triethylamine (TEA) per OH was added and the
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solution was allowed to stir for 10 minutes. At this point, there was a color change,
indicating the hydroxyl groups were deprotonated. The reaction tubes were then placed
inside the CEM microwave reactor and was allowed to react at 90-100 °C for 1 hour per
OH being sulfated. Upon completion, the tubes and their contents were washed with DCM
into a round bottom flask, spotted on TLC to confirm appearance of a sulfated species (10
% methanol in DCM mobile phase; Rf between 15 and 30), and concentrated in vacuo. The
residue was again taken up in minimal DCM and dry-loaded onto silica gel. Isolation of
the sulfated compound utilized normal phase flash chromatography (0-30%
methanol:DCM). Fractions containing the sulfated compound were concentrated in vacuo.
The residue was taken up in minimal water >5 mL (or 3:1 water:methanol) and applied to a
sephadex CM 25 sodium exchange column to produce a sodium sulfate salt from the
alkylammonium sulfate salt. The fractions containing the compound were pooled, frozen at
-80 °C, and lyophilized overnight. This produced a fine, off-white/yellow powder, which
was analyzed by UPLC-MS, 1H-NMR, and 13C-NMR.
The synthesis for the second generation CSAMs (3i and 3j) began by charging a 50
mL round-bottom flask with 250 mg of 3-(3’,4’-dimethoxyphenyl)-7-methoxy-4phenylcoumarin in 5 mL of dry DCM. The flask was then put in -78 °C acetone bath.
While stirring, 7.5 molar equivalence of 1.0M BBr3 in DCM was added dropwise to the
stirred solution, flushed with nitrogen, and allowed to react to room temperature; over the
course of 5 hours. Then, an ice bath replaced the acetone bath to bring the reaction to 0 °C
and 10 mL of 1:1 methanol:water was slowly added to quench the reaction and allowed to
stir for an additional 10 minutes. Upon completion, the solution was condensed in vacuo to
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remove the majority of the organics and the slurry that remained was taken up in 20 mL of
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ethyl acetate and washed with 15 mL of saturated ammonium chloride solution (aq.). The
organic layer was separated and the aqueous phase was washed twice with 10 mL of ethyl
acetate. The organic phases were pooled and washed with brine and dried over Na 2SO4,
filtered, and placed in a 250 mL round bottom flask to be condensed in vacuo. TLC (35%
ethyl acetate:hexanes, Rf = 0.10) showed no starting material and a single spot, so the pale
yellow residue obtained after concentration was used without any further purification;
yield of 93% (206 mg, Figure 8, Step A).
The now 3-(3’,4’-dihydroxyphenyl)-7-hydroxy-4-phenyl coumarin (200 mg) was
placed in a two-neck round bottom flask and 14 mL of diphenylether was added. To this,
1.5 molar equivalence of 1,1-dichloro-1,1-diphenylmethane was added and the flask was
sealed and a reflux condenser was attached. The solution was littered with precipitant until
refluxing conditions (175 °C) were reached in an oil bath for 5 hours, after which the
homogenous solution cooled down to room temperature and crystals began forming. The
crystals were filtered and washed with ice cold hexanes. The remaining crystals were
transferred to a screw cap vial and dried in vacuo overnight, yielding 72% (219 mg, Figure
8, Step B) of a diphenylmethyl (DPM) protected 3-(3’,4’-dihydroxyphenyl) moiety.
The next step was to obtain the alkyne moiety for later usage in the cycloaddition.
For 3i, the alkyne handle was the same as 3g. However for 3j, the alkyne handle contained
the DPM protected 3-(3’,4’-dihydroxyphenyl) moiety, which was synthesized by adding
1.2 molar equivalence of 80% propargyl bromide to a solution of 3 mL dry DMF, 103 mg
of protected coumarin containing free 7-hydroxy, and 1.6 molar equivalence of Cs2CO3.
The reaction took place overnight, and upon completion was quenched with 1.0 M HCl
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and extracted and washed with ethyl acetate. The organic layer was washed with brine,
dried over Na2SO4, concentrated, and dry loaded onto silica for flash chromatography (060% ethyl acetate:hexanes). The fractions containing the desired product were pooled and
concentrated in vacuo for further use (76 % yield, 97 mg, Figure 8, Step D).
Subsequently, the free hydroxyl group on the 7-position of the DPM 3-(3’,4’dihydroxyphenyl) was also used with the electrophilic alkane chain. Thus, 1.2 molar
equivalence of 1-bromo-4-chlorobutane was added to a stirred solution of the protected
coumarin (103 mg) and 1.6 equivalence of Cs2CO3 in 3 mL dry DMF. The solution was
allowed to react overnight and then quenched with 1.0 M HCl. 20 mL of ethyl acetate was
added and the biphasic solution was put into a separatory funnel, where the organic layer
was extracted. The aqueous layer was washed twice with 10 mL of ethyl acetate, after
which the organic layers were pooled, washed with brine, dried over Na2SO4, filtered, and
concentrated in vacuo. The remaining residue was taken up in ~5 mL of DCM and dry
loaded onto silica gel. Flash chromatography was performed (0-60% ethyl acetate:hexanes)
to isolate the protected, alkylated product. The fractions were pooled, concentrated, and
dried under high vacuum overnight (89 % yield, 108 mg, Figure 8, Step C).
The DPM protected butyl chloride coumarin and the DPM protected propargyl
coumarin were both subjected to catechol deprotection by dissolving 108 mg and 97 mg,
respectively in 10 mL of 80% acetic acid and refluxing for 3 hours produced the
deprotected products, identified by TLC (70:30 hexanes:ethyl acetate, Rf 0.35 and 0.33
respectively). The reaction mixture was cooled to room temperature and extracted with 25
mL x 3 of ethyl acetate. The pooled organic layer was washed with brine, dried over
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Na2SO4, filtered, and concentrated in vacuo. The residue was taken up in minimal DCM to
be dry loaded onto silica gel and was purified by flash chromatography (0-100% ethyl
acetate:hexanes). The fractions containing the product were pooled and concentrated in
vacuo, and placed on high vacuum overnight yielding 88 % (69 mg) and 83 % (56 mg),
respectively (Figure 8, Step E).
The deprotected butyl chloride coumarin (69 mg) was dissolved in 3 mL of DMF
and was reacted with 1.5 molar equivalence of NaN3. The reaction was heated at 70 °C for
5 hours in a microwave tube. Once completed the reaction was diluted with 20 mL of ethyl
acetate and washed several times with 10 mL of water to remove excess DMF. The organic
layer was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. No
further purification was performed for this compound. Confirmation of the alkylazide (97
% yield, 68 mg) was done by FT-IR showing the N3 stretch (2100 cm-1) and the up-field
shift of the adjacent CH2 triplet on 1H-NMR (Figure 8, Step F).
Like previously used, the copper-assisted azide-alkyne cycloaddition was employed
for dimerization of 3i precursor by dissolving 68 mg of deprotected butylazide in 1 mL of
DMF. Then 97 mg of dichloro propargyl moiety of 3g was dissolved in 1 mL of DMF. The
two were mixed together in 3 mL of DMSO and 7 mol% of sodium ascorbate dissolved in
water was added to the stirred solution. After 10 minutes, 3 mol% of 1:1
CuSO4∙5H2O:TBTA in a 55% DMSO solution was added to the reaction mixture and
allowed to stir overnight. Upon completion, a few drops of 10% NH4OH was added, the
solution turned blue and 20 mL of cold water was poured into the reaction tube, where a
yellow precipitate formed. After allowed to stir for 10 minutes, the precipitate was filtered
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and kept for further use. The precipitate was taken up in 20 mL of ethyl acetate and 15 mL
of 1.0M HCl was added. The biphasic solution was separated, the aqueous layer was
washed twice with 10 mL of ethyl acetate, and the organic layers were pooled. The
organics were then concentrated in vacuo, dry loaded onto silica gel, and the desired
product was isolated by flash chromatography (0-100% ethyl acetate:hexanes to 0-10%
methanol:DCM). The fractions containing the product were pooled and concentrated,
yielding a yellow residue (65 % yield, 86 mg, Figure 8, Step G).
Likewise for the 3j precursor, 77 mg (from a secondary batch) of the deprotected
butylazide and 56 mg of the deprotected propargyl coumarin were each dissolved in 1 mL
of DMF and mixed together in 3 mL of DMSO. Then, 7 mol% of sodium ascorbate was
added to the stirred solution, where after 10 minutes, 3 mol % of 1:1 CuSO4∙5H2O:TBTA
in a 55% DMSO solution was added to the reaction mixture and allowed to stir overnight.
Upon completion, a few drops of 10% NH4OH was added, the solution turned blue and 20
mL of cold water was poured into the reaction tube, where a yellow precipitate formed.
After allowed to stir for 10 minutes, the precipitate was filtered and kept for further use.
The precipitate was taken up in 20 mL of ethyl acetate and 15 mL of 1.0M HCl was added.
The biphasic solution was separated, the aqueous layer was washed twice with 10 mL of
ethyl acetate, and the organic layers were pooled. The organics were then concentrated in
vacuo, dry loaded onto silica gel, and the desired product was isolated by flash
chromatography (0-100% ethyl acetate:hexanes to 0-10% methanol:DCM). The fractions
containing the product were pooled and concentrated, yielding an off-white residue (98 %
yield, 125 mg, Figure 8, Step G).
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The deprotected, coupled 3-(3’,4’-dihydroxylphenyl) coumarins were then sulfated
using the same method mentioned above. The coumarins 86 mg (3i precursor) and 125 mg
(3j precursor), respectively, were taken up in 3 mL of dry acetonitrile in a microwave tube
with a stir bar. To that was added 12-24 molar equivalence of SO3∙N(CH3)3 and allowed to
stir for several minutes, after which 20-40 molar equivalence of triethylamine was added.
The solution stirred for another 10 minutes and the reaction tube was placed in a
microwave and heated to 100 °C for 2 and 4 hours, respectively. Upon completion, the
mixture was diluted into a round bottom flask with DCM and concentrated in vacuo. The
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residue was then taken up in 5 mL of DCM and dry loaded onto silica gel for separation on
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normal phase flash chromatography (0-30% methanol:DCM). The fractions containing the
sulfated compound were pooled, concentrated in vacuo, and taken up in minimal water.
The solution was then applied to a sephadex CM 25 column charged with sodium acetate,
for sodium exchange of the amine salt. The fractions collected containing the sodium salt
were pooled, frozen in a -80°C refrigerator, and lyophilized. This resulted in a light yellow
powder (97 %, 103 mg, 3i) and an off-white powder (62%, 116 mg, 3j), respectively,
which was stored at -20 °C for future use.
2.2

CSAM Characterization
Characterization of the coumarin-based sulfated allosteric modulators utilized

multiple techniques. 1H-NMR and 13C NMR characterizations was performed with a 400
MHz Bruker NMR, IR measurements were done using a Varian FTIR, and MS data was
obtained from a Waters Triple Quad Mass Spectrometer.
3a1/3b1/3g1 – 1H NMR (Acetone-d6 400 MHz): 7.36 (m, 3H), 7.17 (dd, J = 8 Hz, 1.8 Hz,
2H), 6.91 (d, J = 8 Hz, 2H), 6.88 (d, J = 8 Hz, 1H), 6.82 (d, J = 4 Hz, 1H), 6.74 (dd, J = 8
Hz, 2.36 Hz, 1H), 6.54 (d, J = 8 Hz, 2H).
3c1/3d1 – 1H NMR (Acetone-d6 400 MHz): 7.81 (s, 1H), 7.50 (d, J = 8 Hz, 2H), 7.44 (d, J
= 8 Hz, 1H), 6.77 (d, J = 8 Hz, 2H), 6.74 (dd, J = 8 Hz, 2.32 Hz, 1H), 6.65 (d, J = 8 Hz,
1H).
3e1/3f1 – 1H NMR (Acetone-d6 400 MHz): 7.71 (d, J = 8 Hz, 1H), 7.21 (d, J = 8 Hz, 2H),
6.95 (d, J = 8 Hz, 2H), 6.91 (d, J = 8 Hz, 1H), 6.81 (d, J = 8 Hz, 1H), 2.33 (s, 3H).
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3a2 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (dd, J = 8 Hz, 2.48 Hz, 2H),
6.93 (m, 2H), 6.89 (d, J = 8 Hz, 2H), 6.80 (dd, J = 8 Hz, 2.54 Hz, 1H), 6.52 (d, J = 8 Hz,
2H), 4.28 (t, J = 8 Hz, 2H), 4.02 (t, J = 8 Hz, 2H), 2.21 (quint, J = 8 Hz, 2H).
3b2/3g2 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.84 Hz,
2H), 6.91 (m, 3H), 6.73 (dd, J = 8 Hz, 2.48 Hz, 1H), 6.50 (d, J = 8 Hz, 2H) 4.18 (t, J = 8
Hz, 2H), 3.96 (t, J = 8 Hz, 2H), 1.81 (quint, J = 8 Hz, 2H), 1.72 (quint, J = 8 Hz, 2H).
3c2 – 1H NMR (Acetone-d6 400 MHz): 7.98 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.61 (d, J = 8
Hz, 2H), 7.05 (s, 1H), 7.01 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.88 (d, J = 8 Hz, 2H), 4.32 (t, J =
8 Hz, 2H), 4.08 (t, J = 8 Hz, 2H), 2.34 (quint, J = 8 Hz, 2H).
3d2 – 1H NMR (Acetone-d6 400 MHz): 7.96 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.58 (d, J = 8
Hz, 2H), 7.02 (s, 1H), 6.99 (dd, J = 8 Hz, 2.36 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 4.15 (t, J =
8 Hz, 2H), 3.92 (t, J = 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H), 1.75 (quint, J = 8 Hz, 2H).
3e2 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H), 6.87
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d, J = 4 Hz, 1H), 6.79 (d, J = 8 Hz, 2H), 4.19 (t, J = 8
Hz, 2H), 3.98 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 2.21 (quint, J = 8 Hz, 2H), 2.18 (s, 3H).
3f2 – 1H NMR (Acetone-d6 400 MHz): 7.73 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 6.98
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.93 (d, J = 8 Hz, 2H), 6.91 (d, J = 8 Hz, 1H), 4.22 (t, J = 8
Hz, 2H), 4.01 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 1.98 (quint, J = 8 Hz, 2H), 1.87 (quint, J = 8
Hz, 2H).
3a3 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (dd, J = 8 Hz, 2.48 Hz, 2H),
6.93 (m, 2H), 6.89 (d, J = 8 Hz, 2H), 6.80 (dd, J = 8 Hz, 2.54 Hz, 1H), 6.52 (d, J = 8 Hz,
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2H), 4.28 (t, J = 8 Hz, 2H), 3.78 (t, J = 8 Hz, 2H), 2.21 (quint, J = 8 Hz, 2H). IR (neat):
2102 cm-1.
3b3/3g3 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.84 Hz,
2H), 6.91 (m, 3H), 6.73 (dd, J = 8 Hz, 2.48 Hz, 1H), 6.50 (d, J = 8 Hz, 2H) 4.08 (t, J = 8
Hz, 2H), 3.34 (t, J = 8 Hz, 2H), 1.81 (quint, J = 8 Hz, 2H), 1.72 (quint, J = 8 Hz, 2H). IR
(neat): 2098 cm-1.
3c3 – 1H NMR (Acetone-d6 400 MHz): 7.98 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.61 (d, J = 8
Hz, 2H), 7.05 (s, 1H), 7.01 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.88 (d, J = 8 Hz, 2H), 4.32 (t, J =
8 Hz, 2H), 3.81 (t, J = 8 Hz, 2H), 2.34 (quint, J = 8 Hz, 2H). IR (neat): 2119 cm-1.
3d3 – 1H NMR (Acetone-d6 400 MHz): 7.96 (s, 1H), 7.67 (d, J = 8 Hz, 1H), 7.58 (d, J = 8
Hz, 2H), 7.02 (s, 1H), 6.99 (dd, J = 8 Hz, 2.36 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 4.15 (t, J =
8 Hz, 2H), 3.45 (t, J = 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H), 1.75 (quint, J = 8 Hz, 2H). IR
(neat): 2107 cm-1.
3e3 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H), 6.87
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d, J = 4 Hz, 1H), 6.79 (d, J = 8 Hz, 2H), 4.19 (t, J = 8
Hz, 2H), 3.73 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 2.21 (quint, J = 8 Hz, 2H), 2.18 (s, 3H). IR
(neat): 2112 cm-1.
3f3 – 1H NMR (Acetone-d6 400 MHz): 7.73 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 6.98
(dd, J = 8 Hz, 2.52 Hz, 1H), 6.93 (d, J = 8 Hz, 2H), 6.91 (d, J = 8 Hz, 1H), 4.22 (t, J = 8
Hz, 2H), 3.50 (t, J = 8 Hz, 2H), 2.31 (s, 3H), 1.98 (quint, J = 8 Hz, 2H), 1.87 (quint, J = 8
Hz, 2H). IR (neat): 2130 cm-1.
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3a4/3b4 – 1H NMR (Acetone-d6 400 MHz): 7.23 (m, 3H), 7.10 (m, 2H), 6.95 (m, 2H),
6.88 (d, J = 8 Hz, 2H), 6.78 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.51 (d, J = 8 Hz, 2H), 4.81 (s,
2H), 3.03 (s, 1H).
3c4/3d4 – 1H NMR (Acetone-d6 400 MHz): 7.86 (s, 1H), 7.54 (m, 3H), 6.88 (d, J = 8 Hz,
2H), 6.78 (d, J = 8 Hz, 2H), 4.82 (s, 2H), 3.04 (s, 1H).
3e4/3f4 – 1H NMR (Acetone-d6 400 MHz): 7.61 (d, J = 8 Hz, 1H), 7.05 (d, J = 8 Hz, 2H),
6.89 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.80 (d J = 8 Hz, 1H), 6.78 (d, J = 8 Hz, 2H), 4.82 (s,
2H), 3.04 (s, 1H), 2.30 (s, 3H).
3g4 – 1H NMR (Acetone-d6 400 MHz): 7.64 (d, J = 4 Hz, 1H), 7.29 (m, 3H), 7.17 (dd, J =
8 Hz, 1.92 Hz, 2H), 7.02 (d, J = 8 Hz, 2H), 6.90 (d, J = 2.44 Hz, 1H), 6.65 (d, J = 8 Hz,
2H), 4.79 (s, 2H), 3.09 (s, 1H).
3a5 – 1H NMR (Acetone-d6 400 MHz): 8.37 (s, 1H), 7.39 (m, 6H), 7.29 (s, 1H), 7.22 (m,
4H), 7.11 (s, 1H), 7.04 (m, 4H), 6.97 (m, 7H), 6.88 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.29 (s,
2H), 4.61 (t, 2H), 4.16 (t, 2H), 2.35 (quint, J = 8 Hz, 2H).
3b5 – 1H NMR (Acetone-d6 400 MHz): 8.35 (s, 1H), 7.37 (m, 6H), 7.26 (s, 1H), 7.15 (m,
4H), 7.08 (s, 1H), 7.04 (m, 4H), 6.91 (m, 4H), 6.87 (s, 1H), 6.54 (dd, J = 8 Hz, 2.36 Hz,
1H), 5.29 (s, 2H), 4.50 (t, J = 8 Hz, 2H), 4.15 (t, J = 8 Hz, 2H), 2.05 (quint, J = 8 Hz, 2H),
1.78 (quint, J = 8 Hz, 2H).
3c5 – 1H NMR (Acetone-d6 400 MHz): 8.35 (s, 1H), 8.08 (s, 2H), 7.68 (m, 2H), 7.58 (d, J
= 8 Hz, 4H), 7.18 (s, 1H), 7.05 (m, 3H), 6.84 (d, J = 8 Hz, 2H), 5.29 (s, 2H), 4.61 (t, J = 8
Hz, 2H), 4.14 (t, J = 8 Hz, 2H) 2.38 (quint, J = 8 Hz, 2H).
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3d5 – 1H NMR (Acetone-d6 400 MHz): 8.33 (s, 1H), 8.07 (s, 2H), 7.68 (m, 2H), 7.58 (d, J
= 8 Hz, 4H), 7.18 (s, 1H), 7.04 (m, 2H), 6.85 (d, J = 8 Hz, 4H), 5.29 (s, 2H), 4.50 (t, J = 8
Hz, 2H), 4.13 (t, J = 8 Hz, 2H), 2.06 (quint, J = 8 Hz, 2H), 1.77 (quint, J = 8 Hz, 2H).
3e5 – 1H NMR (Acetone-d6 400 MHz): 8.37 (s, 1H), 8.00 (s, 2H), 7.57 (t, J = 8 Hz, 2H),
7.04 (s, 1H), 7.02 (d, J = 8 Hz, 4H), 6.92 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.89 (m, 2H), 6.74
(d, J = 8 Hz, 4H), 5.21 (s, 2H), 4.58 (t, J = 8 Hz, 2H), 4.08 (t, J = 8 Hz, 2H), 2.35 (quint, J
= 8 Hz, 2H), 2.16 (s, 6H).
3f5 – 1H NMR (Acetone-d6 400 MHz): 8.33 (s, 1H), 7.96 (s, 2H), 7.75 (t, J = 8 Hz, 2H),
7.17 (s, 1H), 7.11 (d, J = 8 Hz, 4H), 7.07 (dd, J = 8 Hz, 2.52 Hz, 1H), 6.99 (m, 2H), 6.84
(d, J = 8 Hz, 4H), 5.30 (s, 2H), 4.51 (t, J = 8 Hz, 2H), 4.14 (t, J = 8 Hz, 2H), 2.25 (s, 6H),
2.04 (quint, J = 8 Hz, 2H), 1.77 (quint, J = 8 Hz, 2H).
3g5 – 1H NMR (Acetone-d6 400 MHz): 8.24 (s, 1H), 8.03 (s, 1H), 7.42 (m, 6H), 7.23 (m,
4H), 7.09 (m, 3H), 7.01 (m, 4H), 6.90 (m, 5H), 5.27 (s, 2H), 4.47 (t, J = 8 Hz, 2H), 4.13 (t,
J = 8 Hz, 2H), 1.99 (quint, J = 8 Hz, 2H), 1.70 (quint, J = 8 Hz, 2H).
3i1/3j1 – 1H NMR (Acetone-d6 400 MHz): 7.24 (m, 3H), 7.09 (dd, J = 8 Hz, 1.8 Hz, 2H),
6.84 (d, J = 8 Hz, 1H), 6.69 (s, 1H), 6.63 (dd, J = 8 Hz, 1.8 Hz, 1H), 6.58 (s, 1H), 6.45 (d,
J = 8 Hz, 1H), 6.32 (dd, J = 8 Hz, 2 Hz, 1H).
3i2/3j2 – 1H NMR (DMSO-d6 400 MHz): 7.49 (m, 11H), 7.33 (m, 3H), 7.20 (m, 2H), 6.90
(d, J = 8 Hz, 1H), 6.83 (m, 3H), 6.75 (dd, J = 8 Hz, 2.4 Hz, 1H), 6.61 (dd, J = 8H, 2.4 Hz,
1H).
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3i3/3j3 – 1H NMR (CDCl3-d1 400 MHz): 7.42 (m, 4H), 7.31 (m, 6H), 7.22 (m, 3H), 7.03
(3H), 6.82 (s, 1H), 6.66 (m, 4H), 3.99 (t, J = 8Hz, 2H), 3.55 (t, J = 8 Hz, 2H), 1.97 (m,
4H).
3j4 – 1H NMR (DMSO-d6 400 MHz): 7.49 (m, 11H), 7.33 (m, 3H), 7.20 (m, 2H), 6.90 (d,
J = 8 Hz, 1H), 6.83 (m, 3H), 6.75 (dd, J = 8 Hz, 2.4 Hz, 1H), 6.61 (dd, J = 8H, 2.4 Hz,
1H), 5.04 (s, 2H), 3.59 (s, 1H).
3i5/3j5 – 1H NMR (CDCl3-d1 400 MHz): 7.33 (m, 3H), 7.14 (m, 3H), 6.93 (s, 1H), 6.79
(dd, J = 8 Hz, 2.4 Hz, 1H), 6.73 (s 1H), 6.57 (d, J = 8 Hz, 1H), 6.39 (dd, J = 8 Hz, 2.4 Hz,
1H), 4.16 (t, J = 8 Hz, 2H), 3.67 (t, J = 8 Hz, 2H), 2.03 (m, 4H).
3i6/3j6 – 1H NMR (Acetone-d6 400 MHz): 7.39 (m, 3H), 7.24 (m, 2H), 7.04 (d, J = 8Hz,
1H), 6.98 (s, 1H), 6.86 (dd, J = 8 Hz, 2.4 Hz, 1H), 6.74 (s, 1H), 6.61 (d, J = 8 Hz, 1H),
6.47 (dd, J = 8 Hz, 2.4 Hz, 1H), 4.22 (t, J = 8 Hz, 2H), 3.49 (t, J = 8 Hz, 2H), 1.98 (quint, J
= 8 Hz, 2H), 1.86 (quint, J = 8 Hz, 2H). IR (neat): 2109 cm-1 and 2115 cm-1.
3i7 – 1H NMR (DMSO-d6 400 MHz): 8.16 (s, 1H), 7.93 (s, 1 H), 7.34 (m, 8H), 7.16 (m,
2H), 7.10 (m, 2H), 7.02 (m, 2H), 6.84 (m, 5H,), 6.54 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.00 (s,
2H), 4.40 (t, J = 8 Hz, 2H), 4.06 (t, J = 8 Hz, 2H), 1.95 (quint, J = 8 Hz, 2H), 1.67 (quint, J
= 8 Hz, 2H).
3j7 – 1H NMR (Acetone-d6 400 MHz): 7.91 (s, 1H), 7.64 (s, 1H), 7.30 (m, 8H), 7.08 (m,
4H), 6.89 (s, 1H), 6.86 (s, 1H), 6.81 (s, 1H), 6.75 (d, J = 8 Hz, 2H), 6.70 (dd, J = 8 Hz, 2.4
Hz, 1H), 6.59 (s, 1H), 6.46 (d, J = 8 Hz, 1H), 6.32 (dd, J = 8 Hz, 2.4 Hz, 1H), 4.99 ( s, 2H),
4.42 (t, J = 8 Hz, 2H), 4.06 (t, J = 8 Hz, 2H), 2.04 (quint, J = 8 Hz, 2H), 1.76 (quint, J = 8
Hz, 2H).
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1a – Sodium 6-chloro-7-methyl-2-oxo-2H-chromen-4-yl sulfate – 1H NMR (DMSO-d6
400 MHz): 7.72 (s, 1H), 7.63 (s, 1H), 6.28 (s, 1H), 2.76 (s, 3H). 13C NMR (DMSO-d6, 100
MHz): 161.35, 159.75, 151.46, 128.79, 122.15, 118.89, 114.85, 96.21, 52.79, 19.86. MS
(ESI) calculated for C10H6ClNaO6S [(M-Na)]-, m/z 289.6519, found [(M-Na)]-, m/z 289.43.
1b – Sodium 3-chloro-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6
400 MHz): 7.81-7.79 (d, J = 8 Hz, 1H), 7.25-7.23 (d, J = 8 Hz, 2H), 2.57 (s, 3H). 13C NMR
(DMSO-d6, 100 MHz): 156.74, 156.37, 151.67, 148.71, 126.38, 117.11, 116.78, 114.36,
106.58, 16.08. MS (ESI) calculated for C10H6ClNaO6S [(M-Na)]-, m/z 289.6518, found
[(M-Na)]-, m/z 289.39.
1c – Sodium 6-chloro-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6 400 MHz):
7.99-7.97 (d, J = 8 Hz, 1H), 7.87 (s, 1H), 7.59 (s, 1H), 6.43-6.41 (d, J = 8 Hz, 1H). 13C
NMR (DMSO-d6, 100 MHz): 159.71, 152.74, 151.98, 143.13, 128.31, 119.64, 114.68,
114.41, 107.76. MS (ESI) calculated for C9H4ClNaO6S [(M-Na)]-, m/z 275.6248, found
[(M-Na)]-, m/z 275.37.
1d – Sodium 6-chloro-4-methyl-2-oxo-2H-chromen-7-yl sulfate– 1H NMR (DMSO-d6
400 MHz): 7.84 (s, 1H), 7.59 (s, 1H), 6.32 (s, 1H), 2.43 (s, 3H). 13C NMR (DMSO-d6, 100
MHz): 159.62,152.52, 152.11, 151.97, 125.60, 119.66, 115.31, 112.92, 107.73, 18.04. MS
(ESI) calculated for C10H6ClO6S [(M-Na)]-, m/z 289.6620, found [(M-Na)]-, m/z 289.39.
2a – Sodium 6-chloro-3-(3,4-dimethoxyphenyl)-4-methyl-2-oxo-2H-chromen-7-yl
sulfate – 1H NMR (DMSO-d6, 400 MHz): 7.81 (s, 1H), 7.53 (s, 1H), 6.97-6.94 (d, J = 12
Hz 1H), 6.85 (s, 1H), 6.78-6.75 (d, J = 12 Hz, 1H), 3.73 (s, 3H), 3.67 (s, 3H), 2.20 (s, 3H).
13C

NMR (DMSO-d6, 100M Hz): 159.80, 151.09, 148.32, 145.09, 126.76, 125.96, 124.84,
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122.68, 119.67, 115.87, 114.05, 111.49, 107.46, 55.63, 55.53, 16.47. MS (ESI) calculated
for C18H14ClNaO8S [(M-Na)]-, m/z 425.8018, found [(M-Na)]-, m/z 425.52.
2b – Sodium 3-(2-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6,
400 MHz): 8.00 (s, 1H), 7.63-7.61 (d, J = 8 Hz, 1H), 7.51-7.37 (m, 4H), 7.22 (s, 1H), 7.147.12 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100M Hz): 159.00, 157.05, 154.21, 142.96,
134.26, 132.86, 131.82, 130.14, 129.26, 129.11, 127.19, 123.65, 116.82, 113.92. MS (ESI)
calculated for C15H8ClNaO6S [(M-Na)]-, m/z 351.7228, found [(M-Na)]-, m/z 351.42.
2c – Sodium 6-chloro-4-methyl-2-oxo-3-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.83 (s, 1H), 7.55 (s, 1H), 7.41-7.32 (m, 3H), 7.26-7.23 (d, J = 8
Hz, 2H), 2.17 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 159.71, 151.75, 151.18,
147.13,134.46, 130.19,130.12, 128.09, 127.87, 126.06, 124.92, 119.76, 115.77, 107.53,
16.39. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found [(M-Na)]-,
m/z 365.48.
2d – Sodium 3-(2-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.38-7.11 (m, 12H), 7.00-6.98 (d, J = 8 Hz, 1H). 13C NMR
(DMSO-d6, 100M Hz): 161.49, 159.42, 156.92, 154.68, 153.58, 133.80, 133.54, 132.65,
132.51, 129.58, 128.82, 128.64, 128.49, 128.30, 127.99, 127.20, 126.62, 116.87, 113.42,
106.96, 102.33. MS (ESI) calculated for C21H12ClNaO6S [(M-Na)]-, m/z 427.8208, found
[(M-Na)]-, m/z 427.53.
2e – Sodium 3-(3-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.32-7.25 (m, 4H), 7.18-7.11 (m, 5H), 7.03-7.01 (dd, J = 8 Hz,
2H), 6.91-6.89 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100M Hz): 177.67, 160.22,
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156.83, 153.39, 151.66, 151.23, 136.60, 134.13, 132.00, 130.39, 129.37, 129.22, 128.96,
128.38, 128.23, 127.89, 127.19, 122.85, 116.62, 115.08, 106.80. MS (ESI) calculated for
C21H12ClNaO6S [(M-Na)]-, m/z 427.8208, found [(M-Na)]-, m/z 427.54.
2f – Sodium 3-(3-chlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.80-7.78 (d, J = 8 Hz, 1H), 7.52-7.43 (m, 3H), 7.31-7.29 (m, 1H),
7.26-7.21 (m, 2H), 2.26 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 13C NMR (DMSO-d6,
100M Hz): 159.89, 156.59, 152.83, 148.59, 139.05, 136.87, 132.71, 130.00, 129.06,
127.79, 126.50, 122.71, 116.40, 114.96, 106.48, 16.42. MS (ESI) calculated for
C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found [(M-Na)]-, m/z 365.48.
2g – Sodium 3-(4-chlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.52-7.51 (d, J = 4 Hz, 1H), 7.47-7.45 (d, J = 8 Hz, 2H), 7.42-7.39
(dd, J = 8 Hz, 1H), 7.32-7.29 (d, J = 8 Hz, 3H), 2.16 (s, 3H). 13C NMR (DMSO-d6, 100M
Hz): 159.79, 149.83, 148.02, 147.97, 133.49, 132.69, 132.31, 132.09, 128.16, 125.19,
124.77, 120.06, 116.74, 116.63, 116.57, 16.44. MS (ESI) calculated for C16H10ClNaO6S
[(M-Na)]-, m/z 365.7498, found [(M-Na)]-, m/z 365.49.
2h – Sodium 3-(2-chlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.74-7.72 (d, J = 8 Hz, 1H), 7.54-7.51 (m, 1H), 7.41-7.32 (m, 3H),
7.20-7.15 (m, 2H), 2.09 (s, 3H). 13C NMR (DMSO-d6, 100M Hz): 159.10, 156.75, 153.02,
149.62, 133.63, 133.29, 132.04, 130.03, 129.23, 127.34, 126.51, 121.85, 116.55, 114.62,
106.64, 16.05. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z 365.7498, found
[(M-Na)]-, m/z 365.49.
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2i – Sodium 3-(2,4-dichlorophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H
NMR (DMSO-d6, 400 MHz): 7.72 (s, 1H), 7.54-7.33 (m, 5H), 2.09 (s, 3H). 13C NMR
(DMSO-d6, 100 MHz): 158.97, 156.96, 153.08, 150.10, 134.48, 133.76, 133.43, 132.75,
128.83, 127.60, 126.57, 120.77, 116.58, 114.49, 106.63, 16.07. MS (ESI) calculated for
C16H9Cl2NaO6S [(M-Na)]-, m/z 400.1918, found [(M-Na)]-, m/z 399.46.
2j – Sodium 3-(2,4-dichlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H
NMR (DMSO-d6, 400 MHz): 7.72 (s, 1H), 7.54-7.33 (m, 5H), 2.08 (s, 3H). 13C NMR
(DMSO-d6, 100 MHz): 158.79, 154.01, 150.00, 149.72, 148.25, 134.28, 133.88, 133.24,
132.65, 128.85, 127.64, 125.32, 123.17, 119.53, 116.81, 16.10. MS (ESI) calculated for
C16H9Cl2NaO6S [(M-Na)]-, m/z 400.1918, found [(M-Na)]-, m/z 399.47.
2k – Sodium 3-(2,4-dichlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H
NMR (DMSO-d6, 400 MHz): 7.32–7.25 (m, 4H), 7.18–7.12 (m, 5H), 7.03–7.01 (m, 2H),
6.91-6.89 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 177.67, 170.10, 160.22,
156.83, 153.39, 151.66, 151.23, 136.60, 134.13, 132.00, 130.39, 129.37, 129.22, 128.96,
128.23, 127.89, 127.19, 122.85, 116.62, 115.08, 106.80. MS (ESI) calculated for
C21H11Cl2NaO6S [(M-Na)]-, m/z 462.2628, found [(M-Na)]-, m/z 461.07.
2l – Sodium 3-(4-chlorophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 7.31-7.26 (m, 4H), 7.17-7.08 (m, 7H), 7.03-7.00 (d, J = 12 Hz,
1H), 6.91-6.88 (d, J = 12 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 161.23, 160.47,
159.94, 154.41, 151.94, 134.40, 133.53, 132.55, 132.52, 132.47, 131.78, 128.97, 128.76,
128.28, 128.22, 127.48, 127.43, 121.15, 113.27, 112.31, 102.20. MS (ESI) calculated for
C21H12ClNaO6S [(M-Na)]-, m/z 427.8208, found [(M-Na)]-, m/z 427.56.
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2m – Sodium 3-(2,4-dichlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6, 400 MHz): 8.02 (s, 1H), 7.68 (s, 1H), 7.63-7.61 (d, J = 8 Hz, 1H), 7.48 (s, 1H),
7.47 (s, 1H), 7.22 (s, 1H), 7.15-7.12 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz):
158.88, 157.14, 154.25, 143.36, 133.96, 133.91, 133.25, 133.14, 129.26, 128.81, 127.42,
122.53, 116.86, 113.84, 106.55. MS (ESI) calculated for C15H7Cl2NaO6S [(M-Na)]-, m/z
386.1648, found [(M-Na)]-, m/z 385.44.
2n – Sodium 3-(4-bromophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6,
400 MHz): 8.20 (s, 1H), 7.65-7.57 (m, 5H), 7.19 (s, 1H), 7.13-7.10 (d, J = 8 Hz, 1H). 13C
NMR (DMSO-d6, 100 MHz): 159.66, 156.87, 153.86, 140.92, 134.08, 131.12, 130.43,
129.15, 122.95, 121.57, 116.76, 114.50, 106.28, 104.80, 99.49. MS (ESI) calculated for
C15H8BrNaO6S [(M-Na)]-, m/z 396.1768, found [(M-Na)]-, m/z 397.38.
2o – Sodium 3-(4-bromophenyl)-2-oxo-4-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6 400 MHz): 7.40-7.36 (m, 6H), 7.23-7.21 (d, J = 8 Hz, 2H), 7.12-7.08 (m, 3H),
6.98-6.96 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 179.59, 160.26, 156.73,
153.33, 151.40, 144.49, 134.22, 133.79, 133.00, 132.79, 130.40, 129.00, 128.37, 128.27,
127.84, 123.08, 120.61, 116.60, 115.13, 106.79, 90.08. MS (ESI) calculated for
C21H12BrNaO6S [(M-Na)]-, m/z 472.2748, found [(M-Na)]-, m/z 471.56.
2p – Sodium 4-(4-chlorobenzyl)-2-oxo-3-phenyl-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6 400 MHz): 7.42-7.39 (d, J = 12 Hz, 1H), 7.36-7.28 (m, 3H), 7.26-7.18 (m, 5H),
7.11-7.09 (d, J = 8 Hz, 2H), 6.99-6.96 (dd, J = 10, 4 Hz, 1H), 3.97 (s, 2H). 13C NMR
(DMSO-d6, 100 MHz): 173.47, 160.75, 160.43, 154.47, 148.44, 137.10, 134.73, 134.62,
130.94, 129.78, 129.71, 128.49, 128.20, 127.85, 127.80, 124.36, 113.05, 111.10, 102.16,
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99.38, 44.22, 33.95. MS (ESI) calculated for C22H14ClNaO6S [(M-Na)]-, m/z 441.8478,
found [(M-Na)]-, m/z 441.63.
2q – Sodium 3-(4-bromophenyl)-4-methyl-2-oxo-2H-chromen-7-yl sulfate – 1H NMR
(DMSO-d6 400 MHz): 7.80-7.78 (d, J = 8 Hz, 1H), 7.67-7.65 (d, J = 8 Hz, 2H), 7.32-7.30
(d, J = 8 Hz, 2H), 7.25-7.22 (m, 2H), 2.26 (s, 3H). 13C NMR (DMSO-d6, 100 MHz):
159.89, 156.58, 155.99, 152.81, 148.33, 134.00, 132.52, 131.06, 126.44, 122.89, 121.16,
116.39, 115.01, 106.48, 101.41, 16.40. MS (ESI) calculated for C16H10BrNaO6S [(M-Na)]-,
m/z 410.2038, found [(M-Na)]-, m/z 409.45.
2r – Sodium 3-(3-bromophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6
400 MHz): 8.31 (s, 1H), 7.96 (s, 1H), 7.77-7.75 (d, J = 8 Hz, 1H), 7.72-7.70 (d, J = 8 Hz,
1H), 7.62-7.60 (d, J = 8 Hz, 1H), 7.46-7.42 (t, J = 8 Hz, 1H), 7.27 (s, 1H), 7.21-7.19 (d, J =
8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 159.65, 157.05, 153.95, 141.49, 137.70,
137.21, 130.93, 130.88, 130.30, 129.25, 127.40, 122.53, 121.41, 116.79, 114.43, 106.28.
MS (ESI) calculated for C15H8BrNaO6S [(M-Na)]-, m/z 396.1768, found [(M-Na)]-, m/z
397.42.
2s – Sodium 3-(3-chlorophenyl)-4-methyl-2-oxo-2H-chromen-6-yl sulfate – 1H NMR
(DMSO-d6 400 MHz): 7.61-7.59 (m, 1H), 7.50-7.48 (m, 3H), 7.45 (s, 1H), 7.40-7.37 (m,
1H), 7.33-7.31 (m, 1H). 2.24 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): 159.71, 149.90,
148.17, 148.05, 136.80, 132.75, 130.02, 129.87, 128.93, 127.92, 125.04, 124.84, 120.01,
116.73, 116.64, 44.20, 16.44. MS (ESI) calculated for C16H10ClNaO6S [(M-Na)]-, m/z
365.7498, found [(M-Na)]-, m/z 365.49.
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2t – Sodium 3-(4-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6
400 MHz): 8.27 (s, 1H), 7.79-7.77 (d, J = 8 Hz, 2H), 7.71-7.69 (d, J = 8 Hz, 1H), 7.54-7.52
(d, J = 8 Hz, 2H), 7.27 (s, 1H), 7.21-7.19 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100
MHz): 167.40, 159.72, 156.85, 153.86, 140.95, 133.70, 132.94, 130.14, 129.15, 128.19,
122.90, 116.76, 114.50, 106.28, 44.21. MS (ESI) calculated for C15H8ClNaO6S [(M-Na)]-,
m/z 351.7228, found [(M-Na)]-, m/z 351.46.
2u – Sodium 3-(3-chlorophenyl)-2-oxo-2H-chromen-7-yl sulfate – 1H NMR (DMSO-d6
400 MHz): 8.33 (s, 1H), 7.83 (s, 1H), 7.73-7.69 (m, 2H), 7.53-7.49 (m, 2H), 7.28 (s, 1H),
7.22-7.20 (d, J = 8 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): 159.65, 157.00, 153.93,
141.50, 136.94, 132.87, 131.07, 130.04, 129.26, 128.06, 127.01, 122.59, 116.77, 114.44,
106.26. MS (ESI) calculated for C15H8ClNaO6S [(M-Na)]-, m/z 351.7228, found [(M-Na)]-,
m/z 351.46.
2v – Sodium 4-(6-bromo-4-methyl-2-oxo-2H-chromen-3-yl)phenyl sulfate – 1H NMR
(DMSO-d6 400 MHz): 7.94 (s, 1H), 7.73 (dd, J = 8 Hz, 1H), 7.36 (d, J = 8 Hz, 1H), 7.17
(m, 4H), 2.22 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): 159.46, 153.39, 151.06, 146.67,
133.93, 130.64, 128.48, 128.14, 126.97, 122.18, 119.88, 119.83, 118.45, 116.31, 26.17,
16.49. MS (ESI) calculated for C16H10BrNaO6S [(M-Na)]-, m/z 410.2038, found [(M-Na)]-,
m/z 409.49.
2w – Sodium 2-hydroxy-4-(2-oxo-4-phenyl-7-(sulfonatooxy)-2H-chromen-3-yl)phenyl
sulfate – 1H NMR (DMSO-d6 400 MHz): 7.38-7.31 (m, 5H), 7.20 (d, J = 8 Hz, 2H), 7.07
(dd, J = 8 Hz, 2.32 Hz, 1H), 6.93 (d, J = 8 Hz, 1H), 6.64 (dd, J = 8 Hz, 2.16 Hz, 1H). 13C
NMR (DMSO-d6, 100 MHz): 160.46, 156.33, 153.16, 150.81, 143.27, 142.42, 134.41,
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129.02, 128.97, 128.20, 128.13, 127.76, 127.47, 124.48, 123.98, 122.72, 118.27, 116.40,
115.30, 106.67, 99.49. MS (ESI) calculated for C21H12Na2O11S2 [(M-2Na)]-, m/z 504.4155,
found [(M-2Na)]2-, m/z 252.51.
2x – Sodium 4-(6,8-dichloro-2-oxo-4-phenyl-2H-chromen-3-yl)phenyl sulfate – 1H
NMR (DMSO-d6 400 MHz): 8.02 (d, J = 2.4 Hz, 1H), 7.44-7.37 (m, 3H), 7.25-7.23 (m,
2H), 7.07 (d, J = 8 Hz, 2H), 7.00 (d, J = 8 Hz, 2H), 6.86 (d, J = 8 Hz, 1H). 13C NMR
(DMSO-d6, 100 MHz): 160.44, 154.36, 150.33, 148.27, 134.89, 132.31, 132.21, 131.93,
130.36, 130.01, 129.88, 129.83, 129.45, 129.24, 128.95, 126.46, 124.46, 123.26, 122.66,
120.26, 120.20. MS (ESI) calculated for C21H11Cl2NaO6S [(M-Na)]-, m/z 462.2628, found
[(M-Na)]-, m/z 461.58.
2y – Sodium 4-(2-oxo-4-phenyl-7-(sulfonatooxy)-2H-chromen-3-yl)phenyl sulfate – 1H
NMR (DMSO-d6 400 MHz): 7.40-7.31 (m, 4H), 7.23-7.21 (m, 2H), 7.08-6.93 (m, 6H). 13C
NMR (DMSO-d6, 100 MHz): 160.62, 156.40, 153.15, 152.58, 150.83, 147.52, 134.60,
131.12, 129.04, 128.55, 128.23, 128.18, 127.71, 123.88, 118.91, 118.89, 118.82, 116.49,
115.36, 114.40, 106.74. MS (ESI) calculated for C21H12Na2O10S2 [(M-2Na)]-, m/z
488.4165, found [(M-2Na)]2-, m/z 244.54.
3a – Sodium 4-(2-oxo-7-((1-(3-((2-oxo-4-phenyl-3-(4-(sulfonatooxy)phenyl)-2Hchromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-phenyl-2H-chromen-3yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.37 (s, 1H), 7.40-7.32 (m, 6H), 7.29
(s, 1H), 7.22-7.19 (m, 4H), 7.11 (s, 1H), 7.04-7.01 (m, 4H), 6.97-6.93 (m, 7H), 6.88 (dd, J
= 8 Hz, 2.4 Hz, 1H), 5.29 (s, 2H), 4.61 (t, 2H), 4.16 (t, 2H), 2.35 (quint, J = 8 Hz, 2H). 13C
NMR (DMSO-d6, 100 MHz): 193.62, 161.07, 160.73, 160.64, 154.10, 154.06, 152.58,
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150.96, 150.94, 147.96, 143.19, 141.93, 134.61, 131.14, 129.02, 128.50, 128.38, 128.36,
128.24, 128.19, 127.46, 125.00, 123.60, 123.13, 123.02, 122.63, 118.84, 114.19, 113.92,
113.81, 112.85, 112.65, 102.77, 101.47, 101.18, 99.50, 67.38, 65.51, 65.49, 59.27, 52.77,
50.97, 48.67, 46.63, 46.59, 42.40, 29.22, 9.92. MS (ESI) calculated for C48H33N3Na2O14S2
[(M-2Na)]-, m/z 939.8985, found [(M-2Na)]2-, m/z 470.45.
3b – Sodium 4-(2-oxo-7-((1-(4-((2-oxo-4-phenyl-3-(4-(sulfonatooxy)phenyl)-2Hchromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-phenyl-2H-chromen-3yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.35 (s, 1H), 7.40-7.31 (m, 6H), 7.29
(s, 1H), 7.21-7.19 (m, 4H), 7.11 (s, 1H), 7.04-7.01 (m, 4H), 6.97-6.94 (m, 4H), 6.92 (s,
1H), 6.90 (dd, J = 8 Hz, 2.36 Hz, 1H), 5.29 (s, 2H), 4.50 (t, J = 8 Hz, 2H), 4.15 (t, J = 8
Hz, 2H), 2.05 (quint, J = 8 Hz, 2H), 1.78 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100
MHz): 203.94, 196.89, 195.80, 175.54, 166.72, 165.45, 161.34, 161.31, 160.73, 157.49,
155.67, 154.06, 152.59, 141.90, 140.87, 139.56, 134.65, 134.61, 131.14, 129.52, 129.22,
129.15, 129.12, 129.03, 128.61, 128.52, 128.50, 128.45, 128.36, 128.31, 128.24, 124.82,
123.13, 120.66, 118.93, 118.83, 113.93, 112.68, 101.52, 101.12, 94.16, 88.00, 67.65,
61.78, 52.77, 51.47, 49.08, 26.41, 7.31. MS (ESI) calculated for C49H35N3Na2O14S2 [(M2Na)]-, m/z 953.9255, found [(M-2Na)]2-, m/z 477.49.
3c – Sodium 4-(2-oxo-7-((1-(3-((2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-chromen-7yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-3-yl)phenyl sulfate – 1H
NMR (DMSO-d6 400 MHz): 8.38 (s, 1H), 8.18 (s, 2H), 7.72-7.62 (m, 6H), 7.25-7.22 (m,
5H), 7.05-7.04 (m, 2H), 6.99 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.30 (s, 2H), 4.62 (t, J = 8 Hz,
2H), 4.17 (t, J = 8 Hz, 2H), 2.37 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz):
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175.55, 159.13, 144.57, 139.90, 139.49, 136.17, 135.28, 132.43, 131.38, 128.92, 128.85,
126.18, 123.16, 122.63, 119.91, 117.12, 116.36, 115.79, 110.72, 109.93, 108.24, 103.12,
102.74, 88.62, 79.35, 78.57, 72.02, 71.32, 66.46, 56.09, 47.12, 42.14, 40.72, 37.56, 13.22,
10.00. MS (ESI) calculated for C36H25N3Na2O14S2 [(M-2Na)]-, m/z 787.7025, found [(M2Na)]2-, m/z 394.24.
3d – Sodium 4-(2-oxo-7-((1-(4-((2-oxo-3-(4-(sulfonatooxy)phenyl)-2H-chromen-7yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-3-yl)phenyl sulfate – 1H
NMR (DMSO-d6 400 MHz): 8.35 (s, 1H), 8.18 (s, 2H), 7.71-7.62 (m, 6H), 7.25-7.22 (m,
5H), 7.04-6.97 (m, 3H), 5.29 (s, 2H), 4.51 (t, J = 8 Hz, 2H), 4.16 (t, J = 8 Hz, 2H), 2.06
(quint, J = 8 Hz, 2H), 1.79 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz): 181.55,
175.12, 174.05, 168.82, 160.00, 154.61, 154.52, 145.95, 141.93, 141.60, 139.90, 129.56,
129.39, 128.85, 124.83, 123.15, 122.93, 119.91, 113.39, 113.10, 112.90, 105.82, 101.07,
100.68, 94.85, 67.61, 61.76, 57.57, 49.07, 45.69, 44.08, 26.43, 25.47, 18.59, 13.88, 7.98,
3.25. MS (ESI) calculated for C37H27N3Na2O14S2 [(M-2Na)]-, m/z 801.7295, found [(M2Na)]2-, m/z 401.27.
3e – Sodium 4-(4-methyl-7-((1-(3-((4-methyl-2-oxo-3-(4-(sulfonatooxy)phenyl)-2Hchromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H-chromen-3yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.38 (s, 1H), 7.79 (d, J = 8 Hz, 1H)
7.76 (d, J = 8 Hz, 1H), 7.26-7.20 (m, 8H), 7.09-6.97 (m, 4H), 5.31 (s, 2H), 4.63 (t, J = 8
Hz, 2H), 4.17 (t, J = 8 Hz, 2H), 2.27 (s, 6H), 2.40 (quint, J = 8 Hz, 2H). 13C NMR
(DMSO-d6, 100 MHz): 161.19, 160.63, 160.22, 153.66, 153.58, 153.06, 147.91, 147.87,
141.98, 130.79, 129.05, 127.00, 126.96, 124.80, 123.09, 122.90, 119.84, 113.84, 113.57,
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112.68, 112.48, 101.33, 100.93, 84.69, 67.56, 61.73, 56.57, 52.78, 49.09, 44.34, 36.61,
26.59, 26.44, 25.48, 16.44, 13.45, 10.45, 3.42. MS (ESI) calculated for C38H29N3Na2O14S2
[(M-2Na)]-, m/z 815.7565, found [(M-2Na)]2-, m/z 408.71.
3f – Sodium 4-(4-methyl-7-((1-(4-((4-methyl-2-oxo-3-(4-(sulfonatooxy)phenyl)-2Hchromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H-chromen-3yl)phenyl sulfate – 1H NMR (DMSO-d6 400 MHz): 8.36 (s, 1H), 7.79 (m, 2H), 7.22-7.19
(m, 9H), 7.09-6.98 (m, 3H), 5.30 (s, 2H), 4.52 (t, J = 8 Hz, 2H), 4.16 (t, J = 8 Hz, 2H),
2.27 (s, 6H), 2.07 (quint, J = 8 Hz, 2H), 1.79 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6,
100 MHz): 168.27, 166.21, 161.19, 160.63, 160.22, 153.66, 153.58, 153.06, 147.91,
147.87, 141.98, 130.79, 129.05, 127.00, 126.96, 124.80, 123.09, 122.90, 119.84, 113.84,
113.57, 112.68, 112.48, 101.33, 100.93, 84.69, 82.62, 67.56, 61.73, 56.57, 52.78, 49.09,
44.34, 26.59, 26.44, 25.48, 16.44, 13.45, 3.42. MS (ESI) calculated for C39H31N3Na2O14S2
[(M-2Na)]-, m/z 829.7835, found [(M-2Na)]2-, m/z 415.29.
3g – Sodium 4-(7-((1-(4-((3-(2,4-dichlorophenyl)-2-oxo-4-phenyl-2H-chromen-7yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-4-phenyl-2H-chromen-3-yl)phenyl
sulfate – 1H NMR (DMSO-d6 400 MHz): 8.24 (s, 1H), 8.03 (s, 1H), 7.41-7.34 (m, 6H),
7.24-7.18 (m, 4H), 7.10-7.08 (m, 3H), 7.03-6.94 (m, 4H), 6.91-6.86 (m, 5H), 5.07 (s, 2H),
4.46 (t, J = 8 Hz, 2H), 4.11 (t, J = 8 Hz, 2H), 1.99 (quint, J = 8 Hz, 2H), 1.71 (quint, J = 8
Hz, 2H). 13C NMR (DMSO-d6, 100 MHz): 185.99, 161.31, 160.64, 159.15, 154.45,
154.14, 150.97, 148.97, 146.95, 142.47, 140.96, 134.63, 133.65, 131.67, 131.45, 131.12,
130.60, 130.11, 129.14, 129.07, 129.02, 128.63, 128.49, 128.33, 128.23, 127.96, 125.11,
124.46, 123,12, 122.95, 121.36, 119.36, 118.82, 114.16, 113.77, 112.64, 104.29, 101.20,
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68.03, 67.65, 61.02, 56.52, 49.03, 47.23, 45.67, 26.37, 25.45, 16.06, 5.86. MS (ESI)
calculated for C49H34Cl2N3NaO10S [(M-Na)]-, m/z 927.7718, found [(M-Na)]-, m/z 928.83.
3i – Sodium 4-(7-(4-(4-((4-(6,8-dichloro-2-oxo-4-phenyl-2H-chromen-3yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)butoxy)-2-oxo-4-phenyl-2H-chromen-3-yl)1,2-phenylene bis(sulfate) – 1H NMR (DMSO-d6 400 MHz): 8.23 (s, 1H), 8.01 (s, 1H),
7.42 (m, 8H), 7.23 (d, J = 8 Hz, 2H), 7.17 (d, J = 8 Hz, 2H), 7.09 (d, J = 8 Hz, 2H), 6.91
(m, 5H), 6.59 (dd, J = 8 Hz, 2.4 Hz, 1H), 5.07 (s, 2H), 4.47 (t, J = 8 Hz, 2H), 4.13 (t, J = 8
Hz, 2H), 2.07 (quint, J = 8 Hz, 2H), 1.73 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6, 100
MHz): 161.26, 160.48, 159.14, 157.45, 154.15, 150.91, 148.95, 146.94, 143.24, 142.52,
142.45, 134.47, 133.65, 131.66, 130.59, 129.07, 128.94, 128.63, 128.49, 128.36, 128.20,
128.05, 127.96, 125.88, 125.11, 124.48, 124.39, 123.07, 122.70, 121.35, 118.29, 113.77,
113.59, 112.58, 101.09, 67.63, 61.04, 49.03, 26.40, 25.46. MS (ESI) calculated for
C49H33Cl2N3Na2O14S2 [(M-Na)]-, m/z 1045.82, found [(M-SO3Na)]-, 942.13 m/z.
3j – Sodium 4-(7-((1-(4-((3-(3,4-bis(sulfonatooxy)phenyl)-2-oxo-4-phenyl-2Hchromen-7-yl)oxy)butyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-4-phenyl-2H-chromen3-yl)-1,2-phenylene bis(sulfate) – 1H NMR (DMSO-d6 400 MHz): 8.33 (s, 1H), 7.38 (m,
13H), 6.96 (m, 5H), 6.74 (m, 3H), 5.33 (s, 2H), 4.49 (t, J = 8 Hz, 2H), 4.13 (t, J = 8 Hz,
2H), 2.03 (quint, J = 8 Hz, 2H), 1.76 (quint, J = 8 Hz, 2H). 13C NMR (DMSO-d6 100
MHz): 203.94, 196.89, 195.80, 175.54, 166.72, 165.45, 161.34, 161.31, 160.73, 157.49,
155.67, 154.06, 152.59, 141.90, 140.87, 139.56, 134.65, 134.61, 131.14, 129.52, 129.22,
129.15, 129.12, 129.03, 128.61, 128.52, 128.50, 128.45, 128.36, 128.31, 128.24, 124.82,
123.13, 120.66, 118.93, 118.83, 113.93, 112.68, 101.52, 101.12, 94.16, 88.00, 67.65,
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61.78, 52.77, 51.47, 49.08, 26.41, 25.43. MS (ESI) calculated for C49H33N3Na4O22S4 [(MNa)]-, m/z 1213.00, found [(M-SO3Na)]2-, 492.72 m/z.
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CHAPTER 3 Evaluation of Inhibition and Thrombin-CSAM Binding Mechanism

Many glycosaminoglycans exist as highly negatively charged ligands, which
typically interact with the surface of proteins through electrostatic forces by pairing with
positively charged residues on the surface of said protein (lysine, arginine, and histidine
residues). These interactions commonly occur at allosteric (distal) sites on the protein
inducing some type of conformational change of the protein. The general theory behind
how these interactions take place is the polyelectrolyte theory, which explains that the
binding is actually an entropic event143. In this theory, we assume that sodium cations are
bound to the sulfate groups in a manner to stabilize the large, negative charge density;
which is thermodynamically unfavorable143. In the event the GAG’s sulfate comes into
contact with a protein’s positively charged surface, for example an arginine, the sodium
ion is displaced and the arginine’s positive charge stabilizes the sulfate’s negative charge;
providing a more favorable interaction. Although these types of binding are generally
homologous interactions (i.e., Na+ v. R-NH4+), the sulfates present on GAGs have been
shown to prefer the guanidinium group of the arginine residues over the ammonium group
of lysine (Arg > Lys > His)143. This lays towards the specificity GAGs possess for their
respected protein interactions.
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GAG recognition and specificity relies on many other factors. First, spacing of Arg
and Lys residues is essential for proper binding and decreases the possibility of nonspecific interactions143. This is also done by the protein surface displaying other residues.
For example, thrombin’s exosite 2 contains hydrophobic patches around key residues, as
well as strategically placed serines, glutamines, and asparagines for enhancement of
binding. Another considerable aspect is the topography of the protein’s surface, by which
the GAG interacts with. For instance, heparin interacts with both thrombin and
antithrombin; this facilitates the inactivation of thrombin by antithrombin through a
heparin-induced, pseudo-intramolecular reaction. This is attained by thrombin having a
lower binding affinity to heparin than antithrombin. Thrombin’s binding affinity (KD) for
heparin is 6-10 µM144, while antithrombin’s binding affinity is ~10 nM95. This 1000-fold
difference in affinities, allows tight binding of antithrombin to heparin, while thrombin is
moves toward the antithrombin reactive loop. This information shows why heparin acts in
an indirect manner. Thus, the binding of heparin to thrombin does not cause a
dysfunctional conformational change of thrombin’s orthosteric (active) site. Many studies
have shown that thrombin’s allosteric (or exo-) sites and the active site are interconnected;
thus binding at one site induces a change to the subsequent sites145, but not seen with
heparin binding to thrombin113.
Taking into consideration the combination of thermodynamic effects of
polyelectrolytes, additional hydrophilic or hydrophobic interactions, and allosteric effects,
compounds can be derived to specifically bind to thrombin’s exosites. The coumarin-based
sulfated allosteric modulators (CSAMs) synthesized herein represent such a group that
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selectively target thrombin, at a specific exosite. Weighing into the conformational
changes they induce, could alter the ability for thrombin to hydrolyze thrombin’s
substrates. Additionally, using minimal sulfates while increasing the hydrophobicity of the
CSAMs eliminates the polyelectrolyte phenomenon, effectively using the sulfate as a
steering group and increases the necessity for other binding examples.
3.1.

Dose-Dependent Inhibition
Thrombin is the major regulatory serine protease within the coagulation cascade.

Its mechanism within the active site utilizes a catalytic triad composed of histidine 57,
aspartate 102, and serine 195, in collaboration with a water molecule to hydrolyze the
carboxy-side of the arginine or lysine residues13,109. This mechanism allows for a much
simpler approach to probing the active site’s function of an activated thrombin. By
obtaining synthetic peptides containing p-nitroanilide groups on the carboxy-side of the
arginine’s, when thrombin hydrolyzes the substrate, p-nitroaniline is released and can be
monitored at 405 nm. This technique has been used extensively for thrombin, as well as
other serine proteases like factor Xa and factor XIa118,120,122,124–127,129,146.
The first generation library of CSAMs was initially screened against thrombin,
factor Xa and factor XIa, which are considered major targets for anticoagulation. The
experiments tested CSAMs at a high concentration of 250 µM in duplicates. Depending on
the enzyme present in the well being screened, appropriate chromogenic substrates were
used; H-D-cyclohexylalanyl-Ala-Arg-p-nitroanilide for thrombin, methoxycarbonyl-Dcyclohexylglycyl-Gly-Arg-p-nitroanilide for factor Xa, and L-pyroGlu-Pro-Arg-pnitroaniline for factor XIa, as performed previously120,124,125,127,129,146.
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For thrombin, the experiments were carried out in 180 µL of buffer (20 mM TrisHCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) at 25 °C, 5 µL of 240 nM
thrombin and 10 µL of CSAM (or vehicle, DMSO) were incubated for 10 minutes. Then,
with the addition of 5 µL of substrate (2 mM), the initial rates obtained from p-nitroaniline
production were monitored over a period of 60 seconds on the Flexstation III plate reader.
For factor Xa, 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1%
PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well followed by 5 µL of 43.5 nM
enzyme and 10 µL of CSAM or vehicle. After a 10 min incubation, 5 µL of 5 mM
substrate was added to each well simultaneously and allowed to react for 300 seconds at 37
ºC. Lastly for factor XIa screens, 85 µL of buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1%
PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well, followed by 7 µL of 15.3
nM enzyme and 3 µL of CSAM or vehicle and incubated for 10 min at 37 ºC. After the
incubation period, 5 µL of 6.9 mM S-2366 was and allowed to react for 300 seconds at 37
ºC. Any sample that showed ≥20% reduction in initial rate compared to vehicle was
considered a “hit”. A total of eleven compounds produced hits, ten were identified for
thrombin, six for factor Xa, and nine for factor XIa.
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These eleven CSAMs were then tested in a dose-response manner to assess the
half-maximal inhibitory concentration (IC50), efficacy of inhibition (ΔY), and Hill slope
(HS) against their respected enzymes, calculated through non-linear regression analysis
𝑌 −𝑌

𝑀
0
𝑌 = 𝑌0 + 1+10(log[𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟
]0 −𝑙𝑜𝑔𝐼𝐶50 )×𝐻𝑆 (Equation 1). Similar to the protocol above, serial

dilutions of stock CSAM in DMSO were prepared (0.04 - 5 mM) giving way to
concentrations ranging from 0.002 - 250 µM in the wells. The experimental data produced
dose-response curves calculating the fractional activity (Y) at each concentration of the

inhibitors tested against each protease; see Table 1.
The analysis provided extremely interesting data. The compounds against factor Xa
were very mild in potency, having all IC50s ≥ 13 µM, and were not very attractive to
pursue further (Table 1). For factor XIa, the CSAMs behaved similarly to SAMs
previously synthesized and tested127,129. The IC50s for monomers were relatively high, 220
and 137 µM, respectively, but this was the first instance of monomeric and monosulfated
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compounds to induce inhibition of factor XIa. The dimeric CSAMs ranged in IC50s from
97 – 31 µM, of which 3g was the most potent SAM identified to date (Table 1). Similarly
to previous SAMs tested127,129,146, the CSAMs showed high Hill slopes owing to the
cooperativity of the dimeric factor XIa, but all possessed ΔY > 80%.
In the case of thrombin, the active CSAMs ranged in IC50s from 0.2 – 58 µM,
describing the most potent SAMs to date (Figure 10). More strikingly however, was the
efficacies of inhibition. The ΔYs ranged from 22 – 73%, suggesting that the CSAM
scaffold inherently induces
partial inhibition. The
exception to this was the
compound 3h, which is 3g
without the sulfate, or
known as 3g5 as depicted by
the NMR data. This could
mean that the binding of
CSAM to thrombin, induces
a slight conformational
change to the orthosteric site, allowing it to remain partially active. This also suggests that
the sulfate is indeed required for proper binding of the CSAM to thrombin.
3.1.1 Structure-Activity Relationships
In order to fully understand what was causing the active CSAMs to inhibit
thrombin, structure-activity relationships (SARs) were assessed for the compounds. SARs
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identify the compound’s structural groups necessary for activity by comparing against
various structural differences at that position on the molecule, which is then compared to
the activity it induces on the target. First, looking at the monomeric sulfated coumarins,
only three were active toward thrombin (2e, 2k and 2p). These three possessed bulky
phenyl (or 4-chlorobenzyl) groups at the 4-position. Also, the monomers all contained
chloro groups, either on the 3-(phenyl) or 4-(benzyl) moiety, suggesting that significant
hydrophobic interactions are at play inhibiting thrombin. It is worth noting that not all
compounds with bulky moieties at the 4-position inhibited thrombin. Additionally,
compounds containing the sulfate at the 7-position were favored over the 6-position, or at
the 4-(4’-hydroxyphenyl) position. Increasing the sulfate count as in 2w or 2y was not
favorable for inhibition of thrombin.
In contrast, all dimeric CSAMs displayed good inhibition potencies (IC50 < 20
µM). Multiple variations were involved with the dimers, including chain length, linker
position, number of sulfates, and 4-position moieties. First linker length varied between 3
and 4 carbons, which did not alter the inhibition significantly. Linker position gave way to
either alkylation at the 7-position yielding head-to-head or 7-7’ dimers, and one head-totail or 7-4’ dimer. Dimers 3a – 3f were 7-7’ dimers consisting of a total of two sulfates,
one at each 4-(4’-hydroxyphenyl) position, while 3g, the 7-4’ dimer contained one sulfate
at the 4-(4’-hydroxylphenyl) position. Lastly, the 4-position varied by phenyl, methyl, and
hydrogen. The original observation that the 4-phenyl group was more potent held true, and
the methyl or hydrogen did not significantly increase the inhibition concentration. Overall,
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3g contained all the structural elements of the most active dimers and monomers including
a sulfated 4-(4’-hydroxyphenyl), 4-position phenyl, and aryl chloride substituents.
3.2 Michaelis-Menten Kinetics
The inhibition profiles of CSAMs show interesting results when compared to other
compounds against the same proteases. For thrombin, the molecule 3g presents a
nanomolar IC50 while allowing the enzyme to remain active. Likewise, 3g also is shown to
be the most potent sulfated allosteric modulator of FXIa to date127,129. Thus, it is of high
priority to understand the binding mechanism of 3g and its represented library. Typically
to achieve this, Michaelis-Menten kinetic studies are performed to observe the enzyme’s
catalytic rate to hydrolyze various concentrations of a substrate and applying the
parameters to the equation: 𝑣0 =

𝑉𝑀𝐴𝑋 [𝑆]
[𝑆]+𝐾𝑀

(Equation 2). This can be performed in the

absence or presence of an inhibitor. As the concentration of the inhibitor increases from the
control, there can be decreases in the VMAX (maximum velocity or = kcat[E]0; kcat is the
catalytic rate and [E]0 is the initial enzyme concentration), the KM (Michaelis constant or
the substrate concentration at ½ VMAX), or both. Decreases in the KM represent competitive
inhibition, decreases in the VMAX represent non-competitive inhibition, and decreases in
both represent un-competitive inhibition.
Considering 3g was the most potent compound against thrombin and factor XIa, we
chose it to represent the CSAM library and test its kinetics, respectively. In a similar
manner to the inhibition studies, 180 µL of thrombin buffer (20 mM Tris-HCl, 100 mM
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NaCl, 2.5 mM CaCl2, 0.1% PEG 8000,
pH = 7.4) was incubated with 5 µL of 240
nM thrombin and 10 µL of vehicle, 0.5,
3.74, or 50 µM of 3g (0.025, 0.187, 2.5
µM in the well) for 10 minutes at 25 °C.
After the incubation period, 5 µL of
Spectrozyme TH dilutions ranging from
0.019 – 10 mM were added and the initial
rate of hydrolysis was monitored at 405
nm for p-nitroaniline production at a
constant 25 °C. The slopes generated from
the Flexstation III were inputted into
SigmaPlot and applied to equation 2. The data revealed that as the concentration of 3g
increased from 0 to 2.5 µM, the KM remained within the measured range for thrombin
activity uninhibited as shown in Figure 11. However, the increase in 3g did cause the
VMAX to decrease in a concentration dependent manner, shown in Figure 11. This supports
a non-competitive mechanism of binding, suggesting allostery.
Likewise, with factor XIa, 85 µL of factor XIa buffer (50 mM Tris-HCl, 150 mM
NaCl, 0.1% PEG 8000, 0.02% Tween 80, pH 7.4) was incubated with 7 µL of 15.3 nM
enzyme and 3 µL of vehicle, 7.5, 15, 30, or 45 µM for 10 minutes at 37 ºC. After the
incubation period, 5 µL of S-2366 ranging from 1.2 – 40 mM was added and monitored at
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405 nm for 300 seconds at a constant
temperature of 37 °C. The slopes
generated by the Flexstation III were
applied to equation 2 in SigmaPlot. The
data from this showed a non-competitive
mechanism of binding as well. The KM
remained within standard deviation of
uninhibited factor XIa. Although, the
VMAX decreased in a concentration
dependent manner. Comparing the
kinetics of 3g with thrombin and factor
XIa, both indeed maintain a noncompetitive mechanism, however, at
saturation of 3g against thrombin, the rate
of hydrolysis does not become diminished beyond ~50%. The same cannot be said for
factor XIa, because as the concentration of 3g reaches saturation, the rate of hydrolysis
continues to become abolished. This further supports the phenomenon of allosteric, partial
inhibition.
3.3

Exosite Competition
As mentioned earlier, thrombin possesses two distinct allosteric sites called exosite

1 and exosite 2. These exosites are selective to a number of different ligands. Exosite 1
binds with fibrinogen Aα, protease-activated receptor 1, the A1 domain of factor XI,

78
thrombomodulin, hirudin, and heparin cofactor II109. Conversely, exosite 2 binds
exclusively with heparin/heparin sulfate, chondroitin sulfate of thrombomodulin,
glycoprotein 1bα, and γ’-fibrinogen109. It is safe to assume that because of these sudden,
yet significant differences in structural features, synthetic compounds can selectively target
one exosite over the other.
To assess whether 3g binds to exosite 1 or 2, competition studies are performed to
investigate such a phenomenon. For exosite 1, hirudin peptide (HirP, [5F]-Hir-(54-65)(SO3-)) is a truncated, fluoresceinylated version of the anticoagulant hirudin, which is
found in the salivary glands of leeches147. The HirP does not possess the portion of the
peptide that interacts and inactivates thrombin’s active site, thus can be used to probe
exosite 1. Likewise, unfractionated heparin (UFH) was used for probing exosite 2
interactions. As mentioned previously, UFH does not interfere with thrombin’s ability to
hydrolyze substrate. The experiments utilized the calculated KD of HirP or UFH for
thrombin and appropriate concentrations are used to show absence of competitor, the KD
concentration, and two-fold the KD concentration. If there is a change in the dose-response
curves, showing an increased IC50, the competitor is competing with 3g at that exosite.
For exosite 1 competition studies, appropriate volumes (175 or 170 µL) of buffer
(20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) were
incubated with 5 µL of 240 nM thrombin, 10 µL of DMSO or varying concentrations of 3g
(50 – 0.2 µM) giving 2.5 – 0.001 µM, and 5 µL of vehicle, 5 µL of 500 nM HirP, or 10 µL
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of 500 mM HirP were added. After
ten minutes of incubation at 25 °C,
5 µL of Spectrozyme TH (2 mM)
was added to the reaction and
monitored for 60 seconds at 405
nm. Slopes generated from the
Flexstation III were input into
SigmaPlot using Equation 1.
Similarly for exosite 2,
adjusted volumes (177 or 174 µL)
of buffer (20 mM Tris-HCl, 100
mM NaCl, 2.5 mM CaCl2, 0.1%
PEG 8000, pH = 7.4) were
incubated with 5 µL of 240 nM of
thrombin, 10 µL of DMSO or
varying concentrations of 3g (50 –
0.2 µM) giving 2.5 – 0.001 µM, and 3 µL of vehicle, 3 µL of 761 µM, or 6 µL of 761 µM
UFH were added. After the ten-minute incubation, 5 µL of Spectrozyme TH was added
and monitored for initial rate of hydrolysis (60 seconds) at 405 nm. The slopes generated
from the Flexstation III were input into SigmaPlot using Equation 1.
Hirudin peptide’s binding affinity for thrombin has been determined to be 12.5 nM,
so the concentration in each set of experiments varied at 0, 12.5, or 25 nM. The dose-
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response profiles generated did not
seem to differ significantly, nor did
the IC50 generated (Table 2 and
Figure 13A). However in the
presence of HirP, the IC50 of 3g
increased by 50% (from 236 nM to
327 and 330 nM). This
phenomenon led us to believe that
the interactions at exosite 1 caused
a slight conformational change to exosite 2, resulting in the decreased potency of 3g to
exosite 2. For this to hold true, there must be competition at exosite 2 with UFH. Analysis
of the dose-response profiles of UFH (at 0, 11.4, and 22.8 µM) showed concentrationdependent increases of the IC50 from 170 nM at 0 µM UFH, to 285 nM and 577 nM for
11.4 and 22.8 µM, respectively (Table 2 and Figure 13B). An interesting observation of
the dose-response profiles of exosite 2 competition was that as the concentration of UFH
increased, the Hill slope also increased. As increased Hill slopes generally mean enhancing
or inducing cooperativity of ligand binding to protein148, this same phenomenon may be
occurring to the system considering 3g has a 100-fold higher binding affinity than UFH (as
shown in Chapter 3, Section 6). Further Dixon-Webb analysis using 𝐼𝐶50,𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 =
(𝐼𝐶50,𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 ) (1 +

[𝑐𝑜𝑚𝑝]
𝐾𝑐𝑜𝑚𝑝

) (Equation 3; Table 2) showed that the 3g did not compete

ideally with exosite 1, thus ruling it out as the binding site, but did in fact compete with
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UFH for exosite 2. This supports exosite 2 as the primary binding site of 3g and that it
indeed binds in an allosteric region of thrombin.
3.4

Mutant Studies
Considering the general binding region of 3g was identified as exosite 2, further

investigation into the specific residues involved with binding was essential. Typically,
mutation studies such as alanine scans, give pertinent information regarding what single
residues are responsible for binding by replacing them with an alanine residue. Our
previous work involving exosite 2 binders have led us to using mutants that have arginines
and lysines of exosite 2 mutated to alanines124,125,128. The information obtained from doseresponse profiles generally show a 2 to 10-fold decrease in potency when the arginine or
lysine involved in binding the sulfate(s) of SAMs is mutated. These residues can be
mapped out to assist in the identification of the specific binding pocket. A few difficulties
are observed with this technique however, especially with 3g considering it only contains
one sulfate. First, mutating surface arginines and lysines may affect the folding of
thrombin or changes in structure and conformation. This must be taken into account
because thrombin’s activity is so highly influenced by small changes on the surface, it may
cause alterations in activity and binding. Second, usually compounds tested using this
method contain multiple sulfates at different positions. This gives way to sulfate-R/K
interaction mapping. With 3g possessing one sulfate, we may be only able to identify one
residue responsible for binding; unless the R/K mutation influences a favorable hydrogen
bonding of ligand to another residue, thus increasing the potency of 3g. Lastly, mutants of
thrombin are recombinant and are expressed in E. coli, which lack the ability to glycosylate
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thrombin. The lack of glycosylation has been shown to cause improper quaternary (4°)
folding of proteins and change thermodynamic properties necessary for ideal function and
propensity149. This may affect thrombin in the same manner.
To obtain useful data from the thrombin mutants, dose-response profiles generated
from incubation with dilutions of 3g in the presence of recombinant wild type thrombin
were compared against the mutants K236A, K235A, R233A, R175A, R173A, K169A,
R165A, R126A, R101A, R97A, and R93A (K240A was found to be completely inactive
and removed from the experimental data). The mutants were kindly provided by the Rezaie
laboratory (St. Louis University), where their individual optical densities (ODs) were
reported. Prior to performing the hydrolysis assays, the concentrations of the obtained
mutants were determined from their ODs and used accordingly. Similar to the previous
dose-response experiments, 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM
CaCl2, 0.1% PEG 8000, pH 7.4) was incubated at 25 °C with 5 µL of 240 nM recombinant
thrombins (determined from OD) and 10µL of DMSO or 3g (0.04 - 5 mM). After ten
minutes, 5 µL of 2 mM Spectrozyme TH was added and monitored at 405 nm for 60
seconds at a constant 25 °C.
As shown in Figure 14, the wild type thrombin results in an IC50 ~400 nM; about
two-fold higher than the IC50 with thrombin obtained from human plasma. Understanding
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this is most likely due to decreased
activity and incomplete quaternary
conformation from lacking
glycosylation, we used this as our
control IC50. The subsequent
thrombin mutants showed varying
effects resulting from 3g interactions
(Table 3). Most notably was the lack
of statistically significant increases of IC50 with a single residue; going against what was
originally predicted to be observed. What we instead observed for R101A and R93A, was
a 2.3-fold increase in potency, yielding an IC50 of 170 nM. We could only make the
rationale that the mutation and loss of the
arginine(s) at those positions resulted in
increasing the binding affinity of 3g to
thrombin, by most likely inducing a more
favorable interaction or conformation.
3.5 Computational Docking
In lieu of the mutant studies not
identifying a specific residue responsible
for binding the sulfate of 3g, we took to
using computational docking and scoring
methods to enrich the data we obtained
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from the mutants’ data. Our lab has previously used docking functions to aid with
identification of allosteric binding sites for glycosaminoglycans, their derivatives, and
GAG mimetics150. Typically two major scoring functions are used, GoldScore and
ChemPLP, which cluster and rank the best binding pose over a number of iterations.
ChemPLP was used first to rank and score the docking poses and GoldScore was
subsequently used to rescore the docking poses. Using the algorithms in this manner
inserts a checks and balance system. ChemPLP is much more efficient at analyzing
hydrophobic and salt interactions, while GoldScore is more efficient at hydrophilic
interactions. Thus because 3g contains mainly hydrophobic with the highly likelihood of
an electrostatic interaction, ChemPLP was chosen as the first filter.
To assess 3g as a ligand for thrombin, it was first drawn in SYBYL-X, a molecular
modeling and docking software. To the structure energy minimization was executed to
give the optimal conformation and torsion angles of the rotatable bonds in the structure.
Then, the x-ray crystal structure of thrombin (3EQ0) bound to a hirudin variant at exosite 1
and the active site was uploaded into SYBYL-X from the Protein Data Bank. The crystal
structure’s ligands such as water, sodium, and the hirudin variant were removed from the
structure and side chains were minimized to their lowest energies. The remaining outlier
rotamers not visible in the original crystal structure, were added minimized and fixed.
Once completed, the file containing the minimized thrombin and 3g were transferred to the
GOLD software program, which contains the executable algorithms for GoldScore and
ChemPLP.
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To perform the initial wild type thrombin docking, a centroid was set in the middle
of exosite 2 with a radius of 20 Å. Upon 3g docking, 300 generic algorithm (GA) iterations
were performed in triplicate and binding poses were clustered with an RMSD ≤ 2.5 Å to
categorize into tight clusters. The initial ranking and scoring was performed using
ChemPLP and was rescored with GoldScore. Subsequently, each alanine mutation was
installed into the thrombin structure individually and the methyl group of the alanine was
used as the centroid of the 20 Å radius. Likewise, 3g was docked into these individual
mutated structures using the parameters as described above. Figure 15 shows the top
scored poses for each set of runs for wild type and the individual mutations.
Analysis of the docking poses show several interesting aspects. To examine the
relevance of exosite 2 binding, we aligned the crystal structure 1XMN, which shows
thrombin bound to heparin with the minimized 3EQ0 crystal structure to define the heparin
binding pocket Figure 15A. Applying the poses of 3g predicted to bind to thrombin
showed that 3g binds in the same binding pocket as heparin. This was regarded as a
positive observation, because experimental evidence shows 3g binding at the heparin
binding site. Upon further investigation, it seems that phenyl O-sulfate of 3g may be
binding in a pocket made up of R126 and R233. This influence of two arginines binding
one sulfate, may explain why mutations at these residues do not alter the IC50s observed in
the mutant studies. We suggest that the sulfate, in the absence of one binding partner
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(R126 or R233), simply
forms a stronger electrostatic
interaction with the
remaining arginine available;
instead of sharing a partial
charge by the two arginines.
To confirm this
experimentally however, a
double mutation (R126A and
R233A) would have to be
obtained and the doseresponse profile would need
to be evaluated. It is
important to note that when
3g lacks a sulfate and is the
hydroxyl, no inhibition is
observed. This suggests that
the sulfate is indeed essential
for binding and inducing
inhibition of thrombin.
Further insight into the
binding of 3g to thrombin
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was obtained by investigating the individual mutations of exosite 2 itself; most notably, the
R93A and R101A mutations. Structurally, these two residues are adjacent to one another
and tend to show similar effects to how 3g binds when they are individually mutated. For
both mutations versus the wild type, the docking showed the triazole ring shifting to a
more favorable position, where the amines can act as hydrogen bond acceptors for K240
and K236. These interactions are posed as too far away (> 4 Å) for the wild type docking,
but still may be involved depending on the rotamers of K240 and K236 (Figure 15B and
C).
Additionally, the unique feature of 3g is that it contains a very hydrophobic tail
with two aryl chlorides in addition to the necessity of the 4-phenyl on the coumarin cores;
suggested to be important for high affinity binding. In the docked poses it shows that both
4-phenyls are set in hydrophobic pockets where π-π and cation-π interactions can have
much greater influence over the compounds that contained the methyl or hydrogen groups
at the 4-position. In reference to the dichloro-tail, it appears to show halogen bonding with
the ammonium group of K87 at an acceptable angle (observed θ = 125-155°; reported θ =
165-180° for R-Cl---NR3) and distance (observed distance ~ 3.2 Å; reported distance 3.27
Å) (Figure 15B and C). All of the tail end docked poses, with the exception of R175A, are
relatively conserved to the K87 ammonium group. It is important to note that with regard
to the halogen bonding angle to the ammonium group, the K87 side chain rotamer is fixed
and under no constriction would most likely have a more acceptable angle (closer to θ =
165-180°). This collective information strongly suggests the necessity of the dichloro
moiety needed to enhance binding. Overall, the docking supports the experimental exosite

88
competition studies and clarifies the results of the mutant studies performed. The data
obtained suggest viable poses and binding partners of 3g to thrombin’s exosite 2.
3.6

Thermodynamic Binding Affinities
According to our IC50 data, 3g binds quite tightly to have such high potency for an

allosteric interaction with an enzyme. To obtain more applicable information of its binding
characteristics, we obtained the binding affinities through fluorescence changes as a ligand
is titrated into the system, taking into account dilution factors. The characteristic loss or
gain in fluorescence intensity as the ligand concentration increases, results directly from
the ligand binding to thrombin. This loss or gain of fluorescence can be then used to
calculate the binding affinity (KD) using the quadratic equation
∆𝐹
𝐹𝑜

=

∆𝐹𝑀𝐴𝑋 [𝑇ℎ]𝑜 +[3𝑔]𝑜 +𝐾𝐷 −√([𝑇ℎ]𝑜 +[3𝑔]𝑜 +𝐾𝐷 )−4[𝑇ℎ]𝑜 [3𝑔]𝑜
{
}
(2[𝑇ℎ]𝑜 )
𝐹𝑜

(Equation 4) because the free

enzyme (initial enzyme) concentration is known.
The binding affinity of 3g was therefore determined by first, addition of 180 μL of
buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4) to a
quartz cuvette and placed inside the fluorometer to measure background fluorescence.
Fluorescence intensities were monitored by excitation at 490 nm and emission at 525 nm
using slit widths of 0.5 mm throughout the experiments. Then 20 μL of 2 μM fluoresceinlabeled (f-FPRck-) human α-thrombin (f-TH) was added to the cuvette, mixed, and placed
into the fluorometer to measure the initial fluorescence intensity. Following this was a
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titration of 1 μL additions of 3g, which
was monitored after each addition, until
the intensity began to remain unchanged
with excess 3g. The KD of the 3g–
thrombin complex was calculated using
Equation 4, in which ∆F is the change
in fluorescence from the formation of
the 3g–thrombin complex with each
addition of 3g. F0 is the initial
fluorescence of f-TH with buffer,
∆FMAX represents the maximum
observed change in fluorescence due to
3g saturation of f-TH, and [Th]0 is the
initial concentration of f-TH unbound.
The binding was assumed to possess a stoichiometry of 1:1. The data obtained from the
fluorescence studies was input into SigmaPlot, using Equation 4. The studies revealed that
3g has a binding affinity for thrombin of 143 ± 12 nM, with a ΔFMAX of ~28%, as seen in
Figure 16A. This thermodynamic affinity is comparable and is within the deviation of the
IC50 (187 ± 40 nM).
With this information in hand along with the docking results, we wanted to
investigate whether addition of a sulfate at the 3-(3’-hydroxylphenyl) position would incur
more beneficial binding, considering the proposed binding pocket of the lone sulfate of 3g
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contained two arginines. As synthesized and described in Chapter 2, Section 1, the
compound 3i contained the 3-(3’,4’-di-O-phenylsulfate). To assess the binding affinity of
3i, the same experiment as stated above was implemented, but instead of titrating in 3g, 3i
was used instead. The results we observed were to our surprise that, 3i showed a > 15-fold
loss in affinity (KD = 2171 nM; ΔFMAX = ~57%) (Figure 16B). This detrimental loss in
affinity suggested that the meta-sulfate adjacent to the para-sulfate was most likely
causing steric clash or hindrance with the binding pocket. This further supported the
likelihood of the phenyl sulfate of 3g binding within the pocket made up of R126 and
R233, because the bisulfate is too bulky to make a proper fit.
3.7

Allostery-Induced Dysfunction of Thrombin’s Orthosteric Site
Understanding the mechanism behind binding and the location of CSAMs binding

to thrombin is an essential aspect of drug discovery. One elusive detail missing from these
GAG mimetics was how the CSAMs were inducing allosteric, partial inhibition of
thrombin. We knew that proteins, like receptors, had the ability to adopt ligand-induced
conformations that allowed the receptor to not produce a signal at maximal efficiency. The
ligand can bind to an allosteric site or to the agonist’s binding site and induce the change
from there134,136. Likewise, ligands can also induce a type of partial inhibition on soluble,
smaller, dimeric enzymes like phosphodiesterase 4137, or hemoglobin, a tetrameric protein
when CO competes with O2 for the heme151.
A significant difference in those systems compared to thrombin is that it is not only
a conformationally flexible protease, but is also monomeric. This dramatically complicates
the understanding of such a mechanism. Typically, partial response or partial ability to
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bind natural substrate is viewed as a cooperative effect. For example with hemoglobin, one
molecule of oxygen binds to one of the four subunits of the tetramer at slow relative rate.
This induces a conformational change, and subsequent oxygen molecules can then bind at
a faster rate; causing a conformational change every time152. For thrombin however, it does
not contain multiple domains or even a dimeric structure. Therefore, comprehending on a
structural level how CSAMs induce submaximal enzymatic activity, without
crystallographic information, casts doubt on the phenomenon. Thus strong experimental
information to support such a claim is desired. The other option is that CSAMs induce
dynamic allostery, which alters the free energy of thrombin’s conformational space
through enthalpic and entropic changes. Distinguishing between the two type of allostery
would greatly assist in understanding the mechanism of the observed partial inhibition.
3.7.1 Collisional Fluorescence Quenching
There are limited techniques available to probe conformational change of a protein
without the use of NMR or x-ray crystallography, that do not require expensive
technologies (i.e. surface plasmon resonance or mass spectroscopy)153–155. To overcome
this hurdle, we implemented a system where an active site fluorophore-bound thrombin
(fTH) could be utilized as an internal probe. The system would work as such, because
when the chloromethylketone of f-FPRck covalently binds to thrombin’s active site serine
(Ser195), the arginine lays within the S1 pocket, proline within the S2 pocket,
phenylalanine within the S3 pocket, and the fluorophore (in this case fluorescein) lays
within the S4 pocket of thrombin’s active site. Under normal and uninhibited dynamic
conditions, the S4 pocket is most accessible to solvent or the environment. Thus, if a
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fluorescein molecule resides in the pocket, it would be available to collisional quenching
agents156. In this case, two collisional quenching agents were sampled, acrylamide and NaI,
however the iodide quencher gave more significant quenching and was used throughout
the experiments157. The basis of the experiments was that if 3g or another SAM were
causing full or partial inhibition, then there would be noticeable differences in the two
SAMs versus the uninhibited thrombin. This is due to the conformational change in and
around the active site, which would cause changes to the iodide’s ability to access the
𝐹𝑜

fluorophore. This could be measured using the Stern-Volmer equation

𝐹

= 1 + 𝐾𝑆𝑉 [𝑄]

(Equation 5), where the change in fluorescence intensity versus the concentration of
collisional quencher is linearized; then the slopes of each experiment could be compared.
To perform the initial uninhibited experiments, 180 µL of buffer (20 mM Tris-HCl,
100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4) was added to a clean quartz
cuvette and the background fluorescence was measured (constant λEX = 490 nm, λEM = 525
nm, 0.5 mm slit widths). To this, 20 µL of 2 µM fTH was added and its basal fluorescence
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intensity was measured. Then, 1 µL of 10
M NaI was added, mixed, and measured
for intensity. This we repeated five times
until equilibrium was reached and no
more loss in fluorescence was observed.
For quenching in the presence of
inhibitors (3g and benzofuran trimer
(BT)), we chose to keep the
concentration of the inhibitors at 90%
saturation (3g = 1 µM for 90% and BT =
2.5 µM for 90%), due to the compounds
precipitating at high concentrations. The
3g experiments were carried out using
177.5 µL of buffer (20 mM Tris-HCl,
100 mM NaCl, 2.5 mM CaCl2, 0.1%
PEG 8000, pH 7.4) in a quartz cuvette,
monitored the same as above. Then 20
µL of 2 µM fTH was added and a reading was taken for the initial fluorescence. Following
2.5 µL of 80 µM 3g, the solution was mixed, incubated at room temperature for 5 minutes,
and measured for fluorescence intensity. Lastly, the 1 µL increments of 10 M NaI were
added and measured individually six times. Similarly for BT (with the exception of
volumes; 173.8 µL buffer and 6.2 µL of 80 µM BT), the experiments were carried out to
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observe the changes in fluorescence intensity (Figure 17A). The intensities measured were
input into an Excel file and dilution factors were taken into account to receive accurate
quenching agent concentrations. The data was then applied to Equation 5, where the term
KSV represents the Stern-Volmer constant, which portrays the slope of the linear
relationship, [Q] is the quencher concentration, F0 is the initial fluorescence and F is the
fluorescence intensity at a particular [Q].
Analysis of the data revealed that fTH in the absence of inhibitor produced a KSV of
2.37 ± 0.14 M-1, corresponding to saturated quenching of the fluorescein. However in the
presence of 3g, the KSV reduced to 1.19 ± 0.06 M-1, see Figure 17B. Such a significant
decrease suggests that 3g induces a conformational change of the protein’s region
surrounding the fluorescein in the S4 pocket. Likewise, fTH in the presence of BT showed
a more significant reduction in the KSV (0.69 ± 0.02 M-1). This result suggests that BT
induces a larger conformational change to the surround residues around S4. In comparison
to the control (absence of inhibitor) to 3g and BT, the 3g’s KSV is 50% of the uninhibited,
while the BT’s KSV is 71% of the uninhibited. If this corresponds to the ΔY values
generated through dose-response profiles, the ΔY of 3g (47%) compares very well with the
percentage of KSV (%KSV) observed in the quenching studies. The comparison of BT’s ΔY
(79%) also matches well with the %KSV of 71%. These results signify that differential
conformational changes can be achieved with small molecule, allosteric modulators of
thrombin, and the extent of the changes depends on the ligand used for inhibition.
3.7.2 Antithrombin Inactivation Rate of Thrombin
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The results discussed above show definitive examples that there is indeed a
modulation of conformational changes to thrombin’s structure, using different exosite 2
targeted ligands; resulting in reduced catalytic efficiency (kcat/KM). However to be
thorough and subject this theory to scrutiny, we chose to develop a label-free assay to
investigate the change to thrombin’s active site induced by 3g using an endogenous
biomolecule known to exclusively interact with thrombin’s active site. This assay utilized
antithrombin III (AT), an endogenous serpin, known to contain an inactivation loop that
covalently inactivates thrombin’s active site serine92,96. The methodology includes using
excess AT in the presence of thrombin over a period of 6 half-lives, to obtain the kinetic
rate of inactivation. If the presence of increased concentrations of 3g (from 0 to near
saturation) show a decrease in the rate compared to an uninhibited system, then 3g is truly
causing allosteric dysfunction of the catalytic triad residues, and embellishes on the
biophysical mechanism of how 3g is partially inhibiting thrombin. It is of importance to
note that the antithrombin reaction is uncatalyzed, meaning unfractionated heparin was not
used within the experiment. We eliminated the use of UFH because in the presence of
heparin, antithrombin inactivation of thrombin is accelerated by ~4000-fold. This would
render us unable to perform this type of experiment because the reaction kinetics would be
too fast to observe.
Initial experiments using the uninhibited system contained a fixed concentration of
6 nM of α-thrombin incubated with 0 mM 3g (vehicle = DMSO) in buffer (20 mM TrisHCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.2) for 10 minutes at 25 °C. The
reaction was initiated by addition of a fixed concentration of 100 nM of AT. For the first
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time point (t = 0 seconds), an aliquot of sample was mixed with 2 mM Spectrozyme TH
and monitored on the Flexstation for 60 seconds at 405 nm. The Spectrozyme was used to
quantify the amount of active thrombin available, and the t = 0-time point would be used to
normalize the data. Subsequent time points were taken at 240, 480, 960, 1920, 3840, and
7680 seconds by removing aliquots of the reaction and mixing with Spectrozyme TH.
Similarly, the inhibited system containing either 75, 225, or 675 nM of 3g were
investigated using the same time points and procedure for monitoring.
Analysis of the raw data involved first inputting the slopes obtained from the
Flexstation into an Excel spread sheet, taking averages of the individual experiments for
each concentration of 3g used. To normalize the data, each averaged slope at its respected
time point was divided into the zero-time point, where t0s/t0s = %normalized 0s, t240s/t0s =
%normalized 240s, etc. The measured activity from the beginning of the experiment to the last
time point was input into the standard exponential decay equation [𝐴] = [𝐴]0 𝑒 −𝑘𝑜𝑏𝑠𝑡
(Equation 6) assuming pseudo-first order rate constant, the observed rate (kobs), at each
concentration of 3g. The intrinsic second-order rate constant of antithrombin inhibition of
thrombin (kint) was calculated by inputting the kobs from Equation 6 into 𝑘𝑖𝑛𝑡 = 𝑘𝑜𝑏𝑠 [𝐴𝑇]0 ,
Equation 7. The intrinsic rate constant (kint) was then plotted against the % concentration of
thrombin–3g complex, obtained from quadratic equation 8,
[𝑇𝐻 − 3𝑔] = {

[𝑇ℎ]𝑜 +[3𝑔]𝑜 +𝐾𝐷 −√([𝑇ℎ]𝑜 +[3𝑔]𝑜 +𝐾𝐷 )−4[𝑇ℎ]𝑜 [3𝑔]𝑜
(2)

}
, to derive the linear

relationship of the different kints of antithrombin inhibition of thrombin–3g complex.
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Figure 18A displays the time profiles of thrombin inactivation by AT at the
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varying 3g levels discussed above. The comparison of the decay profiles using the control
versus the 3g experiments, show a concentration dependent reduction in the rate of
antithrombin inactivation. This suggested that in the presence of 3g, thrombin’s active site
is protected from antithrombin’s inactivation loop. However, to understand if thrombin
remains active, even at 100% 3g saturation, the derived intrinsic rate constant must be used
to compare in an expected linear manner against the calculated thrombin-3g concentration;
which we derived with Equation 8. Figure 18B showed that kint versus the concentration of
thrombin-3g complex as a percent,
would be expected to remain 33 ± 12%
active at saturation. The ability of
thrombin to remain active at 3g
saturation compares relatively well with
the ΔY observed from dose-response
profiles (ΔY = 47%), as well as the
reduction of quenching (%KSV = 50%). This observation fully supports the hypothesis that
an intermediate conformational change of thrombin’s active site induced by the allosteric
effector 3g can cause alteration in the catalytic efficiency and by the same principle, to
thrombin’s ability to cleave substrate. We propose that the inability of antithrombin to
interact and inhibit thrombin in the presence of 3g is directly caused by this conformational
change of the active site (described in Figure 19).
To further validate this, several experiments were performed to assess 3g’s effect
on thrombin inhibition in the presence of antithrombin and 3g’s effects on antithrombin
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itself. This ensured that effects observed in the inactivation assay are due solely to 3g’s
interaction with thrombin. The primary experiment was a dose-response inhibition, similar
to the ones described in Section 1 of this chapter. In brief, 6 nM of thrombin, various 3g
concentrations, and 100 nM of antithrombin were incubated together in thrombin buffer
(20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH = 7.4) over the
course of five minutes at 25 °C. Then Spectrozyme TH was added to the solution and
monitored for p-nitroaniline release at 405 nm. The linear slopes of the residual thrombin
activity for each concentration of 3g were input into SigmaPlot and applied to Equation 1.
As seen in comparative Figure 18E, the IC50s between the (-) AT and (+) AT show no
significant difference, suggesting that the presence of AT does not affect 3g’s ability to
inhibit thrombin.
We then wanted to establish whether 3g was binding to antithrombin. For this we
used a fluorometric thermodynamic binding assay similar to the one used in Section 6.
There was however a significant difference in that the antithrombin did not possess a
labeled fluorophore. We turned to use of 1-anilinonapthalene-8-sulfonic acid (ANS) which
non-covalently binds to protein surface, causing an increase in the basal fluorescence
emission of the molecule (λEX = 405 nm and λEM = 532 nm). Then once the saturation of
ANS to antithrombin is established, a subsequent titration of ligand is added stepwise and
if the molecule is binding, the intensity will decrease. Once ligand binding saturation is
reached, the decreases in fluorescence will cease. Thus, 1 µM of AT was incubated in
thrombin buffer in a quartz cuvette and monitored at the wavelengths described above. To
this, 5 x 1 µL increments of 200, 1000, and 5000 µM was added to the cuvette, mixed, and
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individually measured. To remove background fluorescence, the same procedure was done
in the absence of AT. Once the background was subtracted from the AT sample, it was
plotted as ΔF/ΔF0 versus concentration of ANS (corrected for dilution) (figure not shown).
This displayed what seemed like a biphasic curve, suggesting a high and low affinity
binding site. Focusing on the high affinity site, the calculated concentration of ANS needed
for the displacement assay was 35 µM.
With this information, the displacement assay was constructed using in the quartz
cuvette, thrombin buffer, 1 µM of AT, and 35 µM of ANS. The fluorescence intensities
were taken at each addition of volume and the titration of 3g began using 7 x 1 µL
increments of 8 µM 3g, followed by 3 x 1 µL of 16 µM 3g. Again dilution factors were
taken into consideration and the readings of ΔF/F0 versus the concentration of 3g was input
into Equation 4. The calculated KD from the experiment showed that 3g’s binding affinity
to antithrombin was 74 nM and the ΔFMAX was 17 % (Figure 18C). That is 2-fold higher
affinity than 3g for thrombin. This was worrisome, so one last experiment was developed
to resolve the potential issue.
Through our previous studies on 3g with factor Xa, we knew that 3g’s IC50 for FXa
was ~160 µM, well beyond the KD’s of thrombin and antithrombin. Additionally,
antithrombin inactivates FXa using the same mechanism as it does for thrombin. Thus, we
developed a FXa inactivation assay to probe whether the binding of 3g to antithrombin
affected the rate of inactivation of FXa. The assay was set up the same as above, where
instead of using FXa was incubated in the presence of excess AT and vehicle (DMSO) or
220 nM 3g. We used this concentration of 3g because a significant change in antithrombin
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inactivation of thrombin was seen at the same concentration and we know 3g will not
inhibit FXa at this concentration. The reaction was initiated by incubating 1.1 nM of FXa
with 100 nM of AT with vehicle or 3g. A total of ten time points between 0 and 12600
seconds were taken by aliquoting a volume of reaction and measuring activity with
Spectrozyme Xa. The two sets of raw data were input into SigmaPlot and assessed using
Equation 6. The results shown in Figure 18D, reveal no observable change in the kobs for 0
or 220 nM of 3g.
The results taken herein overwhelming support the theory that 3g was in fact
inducing direct, allosteric, partial inhibition of thrombin. 3g acts by causing dysfunction of
thrombin’s active site where it remains active against small chromogenic substrate, even at
saturated inhibitor concentration. Although experimental results suggest 3g also binds
tightly with antithrombin, there is no evidence that the binding caused a disruption of
antithrombin’s inactivation loop. Most likely, 3g binds to a distal location on antithrombin
that does not cause any significant structural changes that would render the inactivation
loop compromised.
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CHAPTER 4 Endogenous Substrate Hydrolysis: Examination of Inhibition in vitro, ex
vivo, and in vivo

The notion of using thrombin as a key target for anticoagulant therapy arises from
experimental evidence that the alteration of its activity leads to a range of different effects
downstream in the system. It has been shown that thrombin’s reactive specificity is
contingent on its binding partner109,158,159. In the example of thrombomodulin (TM),
thrombin bound to thrombomodulin loses the ability to hydrolyze fibrinogen, but increases
the kcat/KM by ~1000-fold for hydrolysis of protein C160. This phenomenon is theorized to
occur for several reasons. First, thrombomodulin binding to exosite 1 and to some extent
exosite 2 (through interaction with chondroitin sulfate present on 20-35% of TM) may act
as a supplementary exosite for protein C to bind and alter conformation to favorably bind
within thrombin’s active site161,162. Another theory is that TM binding alters thrombin’s
active site to favor protein C hydrolysis and not fibrinogen163,164. Additionally, it has been
suggested that TM may conformationally alter the sodium binding site on thrombin, which
in turn reduces the cationic effects seen by the activation peptide of protein and thus
influences a favorable conformation for protein C to be hydrolyzed160. These effects may
act individually or collaboratively.
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This notable, induced change to the kcat/KM, which results in the lower activation
energy for protein C in the presence of TM was partially the driving force behind the
development of NSGMs and the CSAM library itself. We have shown that 3g induced a
reduction in the catalytic efficiency of thrombin for small substrate, but up until this point,
we have not investigated whether the same type of partial inhibition is carried through for
the endogenous substrates of thrombin. These substrates of particular interest include
fibrinogen, factor XI, protein C, and factor XIII. Therefore, we began studies into the
understanding of the mechanism of 3g-induced partial inhibition of thrombin as it pertains
to endogenous substrates.
4.1

In vitro Fibrinogenolysis
The major substrate for thrombin and the protein responsible for fibrin clots,

fibrinogen exists as a soluble, free-flowing 340 kDa protein in plasma at concentrations of
2-4 g/L165. It is a dimeric protein consisting of three pairs of nonidentical subunits (Aα, Bβ,
and γ). Upon hydrolysis by thrombin, insoluble fibrin monomers are produced and are
subsequently crosslinked through a transglutamination reaction by factor XIIIa. The
crosslinked fibrin forms a mesh with platelets, trapping red and white blood cells, forming
a thrombus or occlusion within a blood vessel. As previously mentioned, current therapies
that target thrombin result in the absence of fibrin production, which can have detrimental
effects on a patient74,85,102. With 3g showing partial inhibition of thrombin against small
substrate, it created curiosity to whether the same phenomenon would occur against
fibrinogen. The possibility that 3g could induce partial fibrinogenolysis, could allow for a

104
more sensitive regulation of thrombosis, without abolishing thrombin’s innate activity
towards the substrate.
To investigate this property of sensitizing thrombin to fibrinogen by 3g, a
transmittance assay was performed in triplicates to examine the amount of fibrin clot
formed in the presence of inhibitor. Human fibrinogen was purchased from Haematologic
Technologies Inc. (Essex Junction, CT) and used in place of Spectrozyme TH as
thrombin’s substrate. In brief, 85 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM
CaCl2, 0.1% PEG 8000, pH = 7.4), 5 µL of 120 nM thrombin, and 5 µL of varying
concentrations of 3g (0.002-250 µM) were mixed in wells of a 96-well plate. Once
thoroughly mixed, 5 µL of 5.3 mg/mL of fibrinogen was added to each well
simultaneously and placed in the Flexstation. To assess transmittance, the plate reader was
set to scan the wells at 600 nm for the first 100 seconds after the addition of fibrinogen.
The slopes generated are directly related to the amount of fibrin clot formed in each well,
thus the amount of light transmitted through the well during clot formation, assessing
thrombin’s rate of activity toward fibrinogen. The slopes and corresponding concentrations
(log10) were inputted into SigmaPlot and Equation 1 was applied to calculate IC50, ΔY, and
HS.
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Much to our surprise, the doseresponse profiles (Figure 20A)
generated from the experiments
showed that 3g indeed inhibited
thrombin from hydrolyzing
fibrinogen, but full, not partial
inhibition was observed (ΔY =
94%). Additionally, the IC50
increased 2.3-fold to 514 nM,
which was a peculiar event
considering the thrombin
concentration was kept at 6 nM
throughout all experiments
performed, as used previously.
After investigation of the
literature, a few explanations could be drawn about why there may be loss of partial
inhibition and loss of potency. About 7% of human fibrinogen contain an additional 20
amino acid sequence called γ’-fibrinogen, caused by an alternative mRNA processing
event in the γ-chain167, as well as significant posttranslational modifications168. This results
in a sequence which contains a tyrosine sulfate and binds with thrombin’s exosite 2 with a
KD of ~0.18 µM and ~0.63 µM168–170, respectively. This γ’-chain may be interacting with
thrombin within the experiment and compete with 3g, causing the increase in IC50.
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A recombinant γ’-peptide with phosphorylated tyrosines (PEHPAETE-Y(PO3-)DSL-Y(PO3-)- PEDDL, replacing the tyrosine sulfates, was obtained from Dr. Farrell at
Oregon Health and Science University, as a free flowing powder. We performed
competition studies using 0, 0.65, and 2 µM of γ’-chain (γ’fibP) using the same protocol as
in Chapter 3 Section 3, however the results were inconclusive and showed no competition.
We then looked at the γ’fibP itself and calculated the molar extinction coefficient at a
wavelength of 280 nm (ε280) for tyrosine and tryptophans present on the peptide. Assuming
the sample was pure, the γ’fibP powder was weighed, and calculated to make an 80 µM
solution using its known average molecular weight (2280.12 Da). The solution was

107
transferred to a quartz cuvette and placed inside a UV spectrophotometer to observe the
absorption at 280 nm. The absorption revealed that compared to a calculated 80 µM, the
concentration in the sample was 70% lower than that according to the Beer’s Law (A =
εLc; where A is absorbance, ε is the molar extinction coefficient, L is the pathlength of the
cell, and c is concentration of solution).
Subsequently, the same solution was injected into the UPLC-MS to analyze the
contents and to verify the peptide was in the sample. The analysis showed that at a
retention time of 3 minutes, two major peaks corresponding to 1191.2 m/z and 1173.1 m/z,
respectively (as seen in Figure 21) were present. After examining the MS data in
conjunction with the chromatograph, we determined that the sample actually contained
~1:1 mixture of N-acetylated (2322.15 Da) and N-free (2280.12 Da) γ’fibP. This was
confirmed by integrating the chromatograph peaks and taking the percentage of the Nacetylated peak corresponding to 1191.2 m/z, which related to the doubly charged species
with hexylamine, [M+C6H13N]2+ and comparing it against the second peak corresponding
to the N-free γ’fibP, 1173.1 m/z, relating to the doubly charged species with sodium
[M+Na]2+. Both peptides are considered to be in their protonated forms, and the MS was in
positive mode, so only one counter ion was observed for each.
After confirming the sample did contain variants of γ’fibP, we adjusted the stock
volumes to use in the competition assay to again use 0, 0.65, and 2 µM and repeated the
assay; assuming the KD = 0.63 µM as described in literature for the peptide. In this
instance, the comparison of IC50s generated from the dose-response profiles with γ’fibP
(Figure 20B), showed a general trend of increasing IC50s as the concentration of γ’fibP
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increased using Dixon-Webb analysis. However the system does not seem to behave as a
truly ideal competitor, as expected for a competitor of exosite 2, because there remains a
significant difference in the observed versus predicted IC50s. Considering the trend seen in
Figure 20B, it can be suggested that the 1:1 mixture of N-acetylated and free-NH2 γ’fibP
causes a slight difference in binding and thus are competitors of 3g against thrombin.
With this information, we then used the average of 7% to calculate the theoretical
amount of γ’-fibrinogen present in the original 5.3 mg/mL (15.59 µM) fibrinogen sample
for the fibrinogenolysis assay. The concentration of γ’-fibrinogen expected to be present
was 0.0546 µM in each well. The IC50 generated from the fibrinogenolysis (514 nM) was
input into the Dixon-Webb analysis (Equation 3) using a KD of 0.2 µM, corresponding to
the literature169. This result showed a predicted IC50 of 655 nM compared to the 514 nM
reported by the assay (Figure 20B). Although not absolutely convincing, the analysis
suggests that the natural γ’-fibrinogen may be competing with 3g at exosite 2. We do know
the exact concentration of γ’-fibrinogen present in the sample considering the
concentration varies by source, but this is a relative estimate and the results support
competition.
These data give support for the reasoning of the 2.3-fold loss in potency of 3g for
thrombin using fibrinogen as the substrate, but does not account for the loss of partial
inhibition. This explanation requires a more theoretical approach. Considering the exosites
and active site are interconnected145, the major binding of fibrinogen to exosite 1, coupled
with 3g binding, may cause an overall structural change. so that the subsequent
conformational change completely blocks the fibrinogen from gaining access to the active
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site; but at lower potency because the conformation of exosite 2 is not favorable for 3g. A
similar event was seen in the HirP competition studies, where the IC50 increased by ~50%,
but did not go beyond that; even as the concentration of HirP increased. The
conformational changes resulting from the HirP at exosite 1, while 3g was binding to
exosite 2, supports an altered binding site for 3g. Although we did not see a loss of partial
inhibition, the sheer size difference between a small peptide and a 340 kDa protein binding
to thrombin at both exosites, may cause enough conformational changes to completely lose
partial inhibition.
4.2

In vitro Protein C Activation
Another protease within the web of coagulation, protein C in its activated form is a

natural anticoagulant found endogenously in the plasma of mammals. The purpose of
activated protein C (aPC), is to inactivate the cofactors for factor IXa and factor Xa, factors
VIIIa and Va respectively; through a proteolytic event. The inactivation of these result in a
vast reduction in the rate of IXa and Xa’s activity; therefore causing a significant loss of
thrombin production in vivo. As mentioned, thrombin is the protease responsible for
activation of protein C through a hydrolysis reaction with its cofactor thrombomodulin.
Upon thrombin binding to thrombomodulin, it is believed that the complex facilitates first
binding with protein C through a supplementary exosite on thrombomodulin, then inducing
a conformational change of protein C. There are also arguments as to whether
thrombomodulin induces allosteric changes to the active site of thrombin upon binding.
According to work done by Fruentes-Prior, P. and Bode, W. et al., the binding of
thrombomodulin to thrombin does not show marketed structural changes to thrombin’s
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active site, as shown by high resolution crystal structures; thereby suggesting the thrombinTM complex’s activity is solely due to conformational changes of protein C caused by
TM171. Opposition to that theory from Koeppe, J. R. and Komive, E. A et al., suggests that
the binding of TM to thrombin causes a long-range tightening of the loop on thrombin
containing residues 126-132, which in turn alters substrate specificity164. This theory was
supported by 1H/2H exchange studies, fluorescent probing of the active site, and
crystallography.
Once in the activated form, aPC utilizes a cofactor, protein S, to facilitate and
accelerate the inactivation of factor Va172. The aPC-protein S complex also overcomes a
biochemical hurdle by increasing the rate of hydrolyzing Arg506 of factor Va by ~20fold173, as well as thwarting the innate protection of FVa’s Arg506 by FXa when in
complex173. Due to aPC’s important role as an in vivo anticoagulant, there is an absolute
necessity to understand how 3g affects not only activated protein C itself, but to discover
whether 3g has any effect on the thrombin-TM complex as it activates protein C.
To probe this system, activated protein C was obtained from Haematologic
Technologies Inc. (Essex Junction, CT) and used in a chromogenic substrate hydrolysis
assay. In 85 µL of buffer (50 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG
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8000, pH 7.2), 5 µL of 500 nM of
activated protein C was incubated
with 5 µL of varying concentrate ions
of 3g or vehicle (DMSO) for 10
minutes. Then, 5 µL of 6.9 mM S2366 was added and monitored at 405
nm for 300 seconds. The slopes
generated from the Flexstation were
input into SigmaPlot and applied to
Equation 1 for IC50, ΔY, and HS.
The dose-response profile generated showed that 3g does not inhibit aPC
significantly, with an IC50 of 346 µM. This aids in confirming 3g’s selectivity towards
thrombin, but also that the activated protein C produced in the following coupled
experiment, would not interfere with the readings obtained. From here we devised a
coupled thrombin-protein assay, where a fixed concentration of thrombin (6 nM) would be
incubated with trabbit-derived thrombomodulin (10 nM) in the presence of a range of 3g
concentrations (0.002-250 µM) or vehicle. To the incubated solution, excess protein C
(400 nM) would be added and the solution would react for 10 minutes. To quench the
reaction, argatroban (800 nM) in a buffer containing 0.02% tween 80 would be added to
inhibit thrombin fully and break up any aggregates. After the quenching, chromogenic
substrate (S-2336) for protein C would be added and monitored at 405 nm for production
of p-nitroaniline. The slopes generated would be fitted to Equation 1 using SigmaPlot.
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Completion of these experiments yielded some interesting results. First the
experiments containing 0 nM thrombomodulin (TM) did not show any response with the
addition of S-2366, signifying that 3g in the presence of thrombin, without TM does not
activate protein C. We anticipated this result, as the activation of protein C requires TM,
but we did not know if 3g would also induce activation of protein C. However, as the
concentration of TM increased to 10 nM, we saw a dose-dependent inhibition of thrombinTM activation of protein C having IC50 of 1.65 µM. Under normal conditions, the
thrombin-TM complex would activate protein C without issue, as seen at low
concentrations of 3g (Figure 22). However in a dose-dependent manner with 3g, the
thrombin-TM complex was inhibited, not allowing for protein C to become activated. This
posed an interesting problem in terms of this scaffold becoming a viable drug candidate. If
3g was inducing inhibition of protein C activation in the presence of thrombin and TM,
then it would be inhibiting a pathway crucial for the homeostasis of coagulation.
On the other hand, if one looks at these results from a biophysical standpoint, the
dose-dependent inhibition of thrombin-TM complex demonstrates several things. It first
validates the potential for a small molecule to induce significant alteration to a protease
complex through allostery. Although the partial inhibition as seen with small substrate was
not carried through to this substrate, the 3g still has a significant impact on the complex.
The 3g-thrombin-TM complex formed in the assays reversed the innate mechanism of
thrombin-TM significantly. This suggests that 3g significantly altered the active site of
thrombin even when TM was bound. The phenomenon of a small molecule, exosite 2
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inhibitor reversing protein C activation is the first of its kind and has not been reported in
literature to our knowledge.
4.3

In vitro Factor XIIIa Activation
The general trend seen with thrombin is that it has many endogenous substrates and

considerably more when bound cofactors. Under normal and thrombotic states, after
thrombin cleaves fibrinogen into fibrin monomers, it also activates factor XIII (existing in
either plasma or on platelet surfaces). The activated FXIII (FXIIIa) is a transglutaminase,
which exists in vivo as a zymogen (FXIII). The plasma zymogen (320 kDa) is a tetramer in
the absence of calcium and consists of two non-identical pairs of α and β subunits (α2β2)62.
Upon the activation of FXIII, thrombin hydrolyzes the bond between the Arg36 and Gly37
of the α subunits and releases a two signal peptides per tetramer. This forms the activated
intermediate FXIIIa (α2’β2), which after binding to calcium causes dissociation of the β
subunits from the α. The FXIIIa now possesses the ability to cross-link the fibrin
monomers through a transglutamination reaction174. This cross-linking accelerates the
build-up of a thrombus by forming the platelet-fibrin mesh. In an up-regulated thrombotic
event, this reaction continues, which eventually can lead to a blockage or a distal
embolism. However, absence of FXIIIa activity causes severe bleeding complications175.
Because of this, thrombin-3g interaction in the presence of FXIII zymogen was studied to
assess whether 3g would induce full, partial, or no inhibition of FXIII activation.
The method of validation utilized SDS-PAGE to observe the activation of FXIII by
thrombin through monitoring the α and β subunit migration on gradient 4-15% gels. Under
non-reducing conditions in the presence of calcium, the two subunits separate giving two
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distinguishable bands on the gel (Figure 23A). When the α subunit is activated by
thrombin, the α2 band loses ~ 8 kDa from the activation peptide cleavage and migrates
down towards the β subunit. This distinct band shift in migration can used to analyze
activity of thrombin in the presence and absence of 3g.
To first understand the kinetics of 1 NIH unit of thrombin (7.8 nM) against 200 nM
of FXIII, the reaction was carried out in 200 µL containing the 7.8 nM thrombin and 200
nM FXIII from 0-30 minutes, and 0, 20-60 minutes taking 20 µL aliquots every 2.5
minutes and 5 minutes, respectively and mixing 1:1 with 2x Laemlli buffer (non-reducing),
and denaturing the sample at 95 °C for 5 minutes. From each sample, 20 µL was
transferred into wells of 7.5% Mini-Protean TGX precast 10-well gels (BioRad) and
electrophoresed using 1x SDS running buffer at a constant 30 mA. After 50 minutes the
gels were washed with high purity water and SDS was removed from the gels by
microwaving the gels in water baths three times and each time allowing them to cool down
for five minutes on an orbital shaker. The water from the baths was discarded and the gels
were stained using Coomassie brilliant blue G-250. After ~1 hour, the gels were destained
and analyzed via an Amersham Imager 600 (GE).
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The first gel showed that after 30 minutes, the appearance of a migratory band
representing the α2’ subunit was beginning to appear. The second gel, which monitored a
longer period of time (0, 20-60 minutes), showed that a time-dependent increase of α2’ was
being produced (see Figure 23A) The reaction was not driven to completion at 60 minutes,
but the substantial visual amount of α2’ present on the stained gel would allow for a dosedependent experiment to be performed using an incubation time of 60 minutes. The
experiment would show whether thrombin in the presence of 3g would inhibit, reduce or
accelerate the production of FXIIIa in vitro.
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In brief, the reaction took place using 600 µL microcentrifuge tubes, solutions of
200 µL buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.3)
contained 7.8 nM of thrombin and varying concentrations of 3g (0-250 µM) or vehicle.
After a five-minute incubation period, FXIII was added to each tube to bring the
concentration to 200 nM and allowed to react for 60 minutes. Aliquots of the reaction were
quenched by mixing 20 µL of the sample with 20 µL of 2x Laemlli sample buffer (nonreducing). Each mixed sample was denatured by incubating at 90 °C for 5 minutes and
then immediately placed on ice until ready for analysis. For gel electrophoresis, a 4-15%
Mini-Protean TGX precast 10-well gel (BioRad) was used to which 10 µL of PageRuler
10-250 kDa (Thermo Scientific) was added to well number 1, while 20 µL of denatured,
mixed sample was added to the subsequent wells (2-10) in the order of increasing
concentration (0-250 µM). The chamber and gel cassette were filled with 1x SDS running
buffer and the gel was run at a constant 30 mA for ~55 minutes. Upon completion, the gel
was removed from its casing, washed with high purity water, heated by microwave briefly,
and was placed on an orbital shaker for 5 minutes. The water was discarded, and the
wash/heating step was repeated twice more. After the last water discard, a solution
containing Coomassie brilliant blue G-250 dye was added to cover the gel, heated briefly,
and placed on an orbital shaker for 1 hour. After the hour incubation, the stain was
removed and high purity was added to destain the gel. The gel was then photographed by
an Amersham Imager 600 (GE) for further analysis.
Images of the gel seemed to reveal a dose-dependent inhibition of FXIII activation,
by analysis of the presence of the α2’ band discussed above. Using Quantity One gel
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analysis software (BioRad), intensities of the α2’ band in each well were compared against
the mean background intensity of the lanes and the α2’ band in the well containing 0 nM
3g. The values were normalized (Xnorm) using the equation 𝑋

𝑋−𝜇

𝑚𝑎𝑥 −𝜇

= 𝑋𝑛𝑜𝑟𝑚 , where X is

the α2’ band intensity of wells containing 3g, Xmax is the α2’ band intensity of the well
containing 0 nM 3g, and µ is the mean background intensity; also known as the minimum
X value. The data received was then input into SigmaPlot to calculate the IC50, ΔY, and
HS, outputting an excited dose-response profile.
As seen in Figure 23B, there is a concentration dependent inhibition of FXIIIa
generation in the presence of 3g. The α2’ band shows partial generation at saturating levels
of 3g indicative of partial activation of FXIIIa by thrombin. The slope generated by
SigmaPlot from the gel shows an IC50 of 0.87 nM and ΔY of 55%. This is the first example
of the thrombin-3g complex showing partial inhibition of hydrolysis for an endogenous
substrate. As exciting as this is, it is important to mention that this is an uncatalyzed
reaction. In vivo, fibrin acts as cofactor, binding to exosite 1 of thrombin and accelerates
the hydrolysis of FXIII by 80-fold109. The lack of fibrin at exosite 1 may distort the results
seen here. The observation that exosite 1 cofactors remove the potential for partial
inhibition is an important aspect of this work and will need further investigation to
understand if the partial inhibition is carried through in the presence of fibrin.
4.4

In vitro Factor XIa Activation
Thrombin has the ability to up-regulate itself through auto-activation of the

intrinsic pathway. In this mechanism, thrombin activates factor XIa (FXIa), causing an
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uninhibited cascade of reactions ultimately activating thrombin from prothrombin and
continuing through that feedback loop176. A means to circumvent this phenomenon is to
inhibit FXIa entirely, because it has been shown to have little bleeding consequences, and
hemostasis remains largely intact177. Although CSAMs are shown to inhibit FXIa, the most
potent inhibitor (3g) does so with a 150-fold less potency of FXIa compared to thrombin.
However, it may stand to reason that 3g’s partial inhibition of thrombin may affect
activation of FXIa by thrombin. Therefore an assay can be used to probe the activation of
FXIa by thrombin in the presence of 3g.
Although this seemed relatively simple, a few caveats were found in the literature.
The relative rate of thrombin activating FXI is very slow; so slow in fact that rate has been
shown to be only 2.5 x 102 M-1s-1 when the concentrations of thrombin and FXI are
1:1178,179. Though, if a polyanionic cofactor is added (i.e., 70-mer polyphosphate or 500
kDa dextran sulfate) to a reaction where thrombin is 40-fold lower concentration than FXI,
the rate drastically increases (7.0 x 105 M-1s-1)178,179. An issue with this however, is that
FXI intrinsically auto activates after 5-10 minutes of incubation with a polyanion179.
Therefore, if use of a polyanion is necessary, a control to monitor the autoactivation must
be taken into account. Lastly, considering FXI is a dimer with one active site on each of its
monomeric subunits, traditional monitoring via chromogenic substrate would not allow for
us to distinguish between ½ FXIa of full FXIa.
To circumvent the hurdles with FXI activation, the initial steps taken involved first
studying the plasma-obtained FXI in the presence of 1 NIH unit of thrombin alone. This
required an 8-hour study to observe how much ½ FXIa and full FXIa was generated, by
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observing activation of FXI on
SDS-PAGE. As FXI is activated
to first ½ FXIa and then FXIa,
there is a conformational change
that allows differential
migration on low percentage
gels, as seen in Figure 24A.
Additionally, being ½ FXIa and
FXI migrate very similarly on
the gels, active site fluorophore
implementation was used.
Fluorescein-labeled FPRck or
dansyl-EGRck was used to
enhance sensitivity for visualization of the bands as seen in Figure 24A.
Two experiments were undertaken to assess the thrombin-3g complex effects on
FXI. The first was to observe dose-dependence of the uncatalyzed complex on FXI over a
5-hour period using 1 NIH unit of thrombin and 200 nM of FXI. The second experiment
looked at the same dose-dependence effects, but using 1 µg/mL of dextran sulfate (DS;
mol. Wt. 500 kDa) as a the polyanionic cofactor over a 5 and 10-minute period. The
experiments proceeded by taking a fixed concentrations of thrombin (7.8 nM) in buffer (50
mM Tris-HCl, 100 mM NaCl, 0.1% PEG 8000, pH 7.4) and incubating with increasing
amounts of 3g (0-250 µM), and a fixed volume of FXI zymogen (owing to 200 nM) at 37
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°C. For the catalyzed experiment, 5 µL of 20 µg/mL of DS was added to each reaction to
give 1 µg/mL in each tube. To quench all of the reactions, 3-fold molar equivalence of
fluorescein-FPRck would be added and allowed to react over 30 minutes at room
temperature. The tubes were mixed 1:1 with 2x Laemlli buffer (non-reducing) and 20 µL
of mixed sample were loaded on 7.5% Mini-Protean TGX precast 10-well gel (BioRad)
and run at 30 mA for 60 minutes using 1x SDS running buffer. The gels were removed of
SDS by washing and heating with distilled water 3x. The gels were scanned using the
fluorescent setting of the Amersham 600 gel imager (GE). The gels were then stained with
coomassie G-250, destained, and imaged with the Amersham 600.
Upon imaging the uncatalyzed and catalyzed gels, the bands for each individual
concentration of 3g appeared to not be significantly different from one another. To obtain
clarification of this, we employed the use of Quantity One gel analysis software (BioRad)
to analyzed the individual bands, by comparing against the 0 nM 3g and the background.
First, the uncatalyzed gels showed a dose-dependent decrease in the amount of ½ FXIa
produced by the reaction. Normalizing the intensities and comparing them versus the
concentration of 3g showed partial inhibition with an IC50 of 0.782 µM (Figure 24 B and
C). Alternatively, for the catalyzed gels, partial inhibition was still observed, but with an
IC50 of 28 µM (Figure 24 B and D). This suggested that the dextran sulfate played a major
role in competing with 3g for exosite 2 of thrombin and that 3g induced catalytic
dysfunction to thrombin’s active site resulting partial inhibition. This competition and
change in IC50 is similar to what is seen in the competition studies with UFH.
4.5

Ex vivo Human Plasma Studies
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One of the most important aspects involving anticoagulant drug discovery is not
necessarily understanding the precise target protein or complex, but finding out if the novel
agent retains its ability to inhibit clot formation in plasma and blood. It is crucial in the
development process to gather as much information as possible regarding the drug’s
potency and if there are other proteins within the blood or plasma that it may be binding to.
In this case, the CSAMs are known to bind thrombin tightly, but it also behaves relatively
promiscuous with other coagulation proteins. To investigate this further, we used an ex
vivo assay and human citrated plasma to probe whether the CSAMs act towards the
intrinsic or extrinsic pathways. This is performed by measuring the activated partial
thromboplastin time (aPTT) for the intrinsic pathway, and prothrombin time (PT) for the
extrinsic pathway. In brief, citrated human plasma is used to chelate any calcium ions
within the plasma, to ensure there is no premature activation of coagulation enzymes. The
two assays differ in how they are initiated. The aPTT assay incubates with ellagic acid, to
simulate “contact”-activation. Once the plasma and reagents are incubated and mixed
properly, a calcium chloride solution is added, which triggers a procoagulant response.
Alternatively, the PT assay incubates the citrated plasma with thromboplastin-D (tissue
factor) and is then initiated by addition of calcium.
To begin, one-stage recalcification assays were performed, using a BBL fibrometer
(Beton-Dickinson, Sparles, MD). To measure the aPTT, a number of various 3g
concentrations or vehicle (DMSO) were added to citrated human plasma and aPTT reagent
(0.2% ellagic acid) which is incubated at 37 ºC for 4 min. Prewarmed 25 mM CaCl2 is
added to initiate clot formation. The time to clot formation was then recorded in seconds.
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In the PT assay, 3g or vehicle is added to
citrated human plasma and incubated at
37 ºC for 30 sec. After the short
incubation period, the pre-warmed
thromboplastin-D solution was added
and the clotting time is established. The
concentration required to double the
clotting time (2xaPTT or 2xPT) was considered the effective concentration in plasma180.
Results from the plasma studies revealed that 3g targeted the intrinsic pathway,
having a 2xaPTT of 220 µM compared to the PT having a 2xPT of 660 µM; see Figure 25.
This ensured that 3g indeed behaved as an anticoagulant, but displayed a 1000-fold loss in
potency in plasma. In order to evaluate this loss, we looked at the binding of 3g to serum
albumin, considering that ~55% of plasma consists of albumin and is the likely candidate
for binding exogenous compounds like drugs181. An intrinsic fluorescence experiment used
albumin at plasma concentration (45 mg/mL) with titrations of 3g, up to 250 µM. The
study showed that KD was 184 µM, well above the KD for 3g to thrombin (147 nM). This
led us to believe that the 3g was not binding to serum albumin. Therefore, the binding must
be occurring with immunoglobulins in the plasma or with some other serum protein. More
investigations into the binding partner would need to be established to identify the
mechanism, but falls out of the scope of these basic ex vivo experiments and more into a
pharmacokinetic aspect.
4.6

Ex vivo Whole Blood (Thromboelastography) Studies
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To establish the efficiency of coagulation, fibrin build-up, and clot strength (i.e.,
thrombodynamic properties) in the presence of 3g, thromboelastography (TEG) was used.
These studies were performed in the laboratory of Dr. Don Brophy (School of Pharmacy,
VCU). Briefly, the thrombodynamic properties were monitored as a blood sample is
induced to clot through a recalcification assay. The study was kept at a low-shear
environment, representing a sluggish venous flow. The properties are expected to
drastically change when comparing a blood sample with and without an inhibitor. Clot
formation was monitored via a pin connected to a torsion wire located at the center of a
cup, where the blood is held. The strength and elasticity of the clot applies a force to the
pin and changes its rotation, which is subsequently monitored and recorded. The data is
then applied to a set of parameters; maximum amplitude (MA) of clot formation (i.e.,
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stability), amplification of clot strength (G), initial reaction time to the start of clotting (R),
and the angle (α), which is representative of fibrin build-up and cross-linking182.
The experiments utilized the 2-fold below the aPTT concentration to begin the
experiment, and increased to the 2xaPTT concentration and increased each subsequent
concentration by the same factor. The analysis showed an anticoagulant TEG profile
beginning to take effect at ~3x the 2xaPTT concentration, and equivalent to the 2xPT
concentration at 627 mg/mL (Figure 26). Clot initiation time was doubled for 0.627
mg/mL tripled for 0.836 mg/mL and at 1.045 mg/mL was having a 6-fold increase
compared to the control. Additionally at 1.045 mg/mL of 3g, the maximum amplitude and
angle both drastically decrease, which may be indicative of having both anticoagulant and
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antiplatelet effects (Table 4). However, that is only based off of this empirical evidence
and was not further investigated due to the extremely high concentration. It is however
important to note that 3g does behave as an anticoagulant in whole blood, albeit being at a
substantial dose.
4.7

Mouse Tail-Bleed Studies
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A common judgement of the
efficacy of an anticoagulant is the
utilization of a mouse tail-bleed
assay, which is relatively noninvasive, very simple, and contain a
considerable amount of
information183. The experimental
procedure is rudimentary and straight
forward. A number of mice are dosed with either controls (positive: argatroban or negative:
vehicle) or with drug by injection to the tail vein. A short period of time passes, imitating
an incubation period, and the tip of their tail is cut. Once the initial cut is made, the timer
starts and continues until a clot has formed. These times are then compared to observe if
the drug causes any type of excessive bleeding at the concentration dosed.
For experiments involving 3g, the CSAM was dissolved in 30% ethanol and diluted
to 14% to be given as a 2 mg dose/mouse. An injection of the same volume containing
either 14% ethanol as a negative control or 0.66 µg of argatroban as a positive control were
used. The single doses were given as bolus injections to the tail vein, and incubated for 5
minutes prior to the tail cut. The times were recorded for each bleed. Analysis of the
control bleeds versus the 3g doses showed no significant bleeding for any of the
experiments. There were no statistically significant changes in 3g from the negative control
or from the positive control as seen in Figure 27. This indicates that at the dosage in mice,
3g does not cause excessive bleeding, but neither did the pharmacologically relevant dose
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of argatroban; which is not surprising being < 5% of patients see adverse bleeding with
argatroban and only 4 data points were taken for the positive control. To gain more
confidence in these experiments, higher doses of 3g, as well as argatroban would need be
done to obtain clinical relevance. An indirect observation was that even at a 2 mg dose, the
mice seemed unaffected and did not display any acute symptoms even after having an
average of 1.4 mM of 3g in their systems.
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CHAPTER 5 Conclusions and Future Work

Exploitation of thrombin’s exosites and inherent plasticity may be a key factor in
regulation of its endogenous activity and maintaining hemostasis in vivo. Previous studies
have used similar techniques, which utilize the notion of partial inhibition for alleviation of
side effects; while still asserting response from the target protein137. The results reported
herein tie together a number of theories with regard to a new, plausible mechanism for how
to inhibit thrombin while reducing or eliminating the risk of abnormal bleeding. The
potential to remove the risk of bleeding comes from the idea that partial inhibition allows
for either reduced catalytic efficiency for a specific substrate, or the active site
conformation may become unfavorable for interaction with certain substrates (i.e.,
inducing previously unobserved selectivity).
From a mechanistic point-of-view, a monomeric protease displaying partial
inhibition suggests that the protease is behaving as an oligomeric protein. This is most
likely due to the large conformational dynamics inherent to the protease. However, as seen
in the fluorescence quenching experiments and the antithrombin inactivation, the
conformation of and around the active site is changing dramatically. Leaving only the
observation that structural conformational change is being induced, and inhibition is not
due to conformational dynamics. This is fully supported by the collisional quencher not
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being able to gain access to the fluorescein at the S4 pocket. Additional support for this is
the significant change observed to thrombin-3g complex’s recognition of protein C when it
is bound to thrombomodulin. The 3g induced a complete change to thrombin’s recognition
for protein C from activation under normal conditions, to inhibition of protein C activation
in the presence of 3g. Similarly, the partial inhibition of FXI and FXIII activation versus
the full inhibition of fibrinogen cleavage versus recognition of protein C suggests that the
alteration of thrombin’s structure induced by 3g may cause a meta-stable state of thrombin
where its activity is suppressed or altered. Therefore, the extent of inhibition may have a
direct correlation to the cofactors bound to exosite 1 and how that alters the thrombin-3g
complex. Crystallographic data may be able to clarify the exact mechanism of 3g-induced
partial inhibition and work on the co-crystal structure is currently underway using
thrombin-3g and thrombin-TM-3g complexes.
From a drug development aspect, 3g is the most potent exosite 2 inhibitor of
thrombin to date, but does not seem to present a viable route to the clinic; considering its
loss of potency in plasma and blood, partial inhibition of FXIII activation, inhibition of
protein C activation, and partial inhibition of FXI activation. The identification of the
endogenous mechanism by which 3g binds significantly is needed, so further alterations of
the structure can be performed to regain the nanomolar KD’s seen in vitro. The use of 3g
does present itself as a valuable tool for probing thrombin and the newly discovered
possibility to induce allosteric partial inhibition. If a compound could be derived from 3g
that serves as a partial inhibitor towards fibrinogen or a selective inhibitor to reduce the
feedback loop of thrombin up-regulation through FXI, FV, and FVIII activation, there will
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be great clinical potential in that aspect. Maintaining thrombin’s activity towards
fibrinogen without the side effects of the bleeding in addition to reduction of thrombin
propagation would make for an ideal anticoagulant. Future work on these compounds of
the partial inhibition of thrombin is needed to exploit the features mentioned here.
Additional work into how 3g affects FV and FVIII activation is crucial in this. Ultimately
obtaining structural information through NMR or x-ray crystallography is of key
importance to aid in the design of more potent and selective partial inhibitors.
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APPENDIX A

Ultra-Pressure liquid chromatography (UPLC) coupled to a low-resolution mass
spectrometer (MS) produced the following spectra. The spectra are labeled on the right for
the name of the compound with UPLC or TIC, representing the chromatograph and totalion count, respectively. The solvent system contained 0.01% formic acid with a gradient of
10:90 acetonitrile:water, to 90:10 acetonitrile:water.
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APPENDIX B

The following 1H-NMR and 13C-NMR graphs are taken from a Bruker 400 MHz
NMR, processed to show the integrations of each peak relevant the compound named on
the upper-right. Full characterization is found in Chapter 2, Section 2. Unlabeled peaks are
solvent or impurities within the solvent (> 99 % d6-DMSO).
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